{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,7]],"date-time":"2026-11-07T03:47:48Z","timestamp":1794023268865,"version":"4.8.0"},"reference-count":226,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,5,29]],"date-time":"2026-05-29T00:00:00Z","timestamp":1780012800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,7,31]],"date-time":"2026-07-31T00:00:00Z","timestamp":1785456000000},"content-version":"vor","delay-in-days":63,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"DOI":"10.13039\/100020581","name":"Fondazione AIRC per la ricerca sul cancro ETS","doi-asserted-by":"publisher","award":["28054; 29829"],"award-info":[{"award-number":["28054; 29829"]}],"id":[{"id":"10.13039\/100020581","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100020581","name":"Fondazione AIRC per la ricerca sul cancro ETS","doi-asserted-by":"publisher","award":["26343"],"award-info":[{"award-number":["26343"]}],"id":[{"id":"10.13039\/100020581","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100020349","name":"Fondazione Italiana per la ricerca sulle Malattie del Pancreas","doi-asserted-by":"publisher","award":["J38D19000690001"],"award-info":[{"award-number":["J38D19000690001"]}],"id":[{"id":"10.13039\/100020349","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100006747","name":"Fondazione Cassa di Risparmio di Verona Vicenza Belluno e Ancona","doi-asserted-by":"publisher","award":["203885"],"award-info":[{"award-number":["203885"]}],"id":[{"id":"10.13039\/501100006747","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Mol Cancer"],"DOI":"10.1186\/s12943-026-02697-4","type":"journal-article","created":{"date-parts":[[2026,5,29]],"date-time":"2026-05-29T02:17:45Z","timestamp":1780021065000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":4,"title":["Multi-omic profiles of neuroendocrine neoplasms of the pancreas: an integrated landscape"],"prefix":"10.1186","volume":"25","author":[{"given":"Michele","family":"Bevere","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anastasios","family":"Gkountakos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Silvia","family":"Valentinuzzi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Simone","family":"De Fabritiis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chee S.","family":"Wong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Riccardo","family":"De Robertis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paola","family":"Mattiolo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Manuel","family":"Gentiluomo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matteo","family":"Fassan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Antonio","family":"Pea","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stefano F.","family":"Crin\u00f2","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michele","family":"Simbolo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrea","family":"Mafficini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniele","family":"Campa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sara","family":"Cingarlini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luca","family":"Landoni","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rita T.","family":"Lawlor","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Roberto","family":"Salvia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mirko","family":"D\u2019Onofrio","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michele","family":"Milella","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Volkan","family":"Adsay","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lodewijk A.","family":"Brosens","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christopher M.","family":"Heaphy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Seung-Mo","family":"Hong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aatur D.","family":"Singhi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aldo","family":"Scarpa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Claudio","family":"Luchini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,5,29]]},"reference":[{"issue":"12","key":"2697_CR1","doi-asserted-by":"publisher","first-page":"991","DOI":"10.1016\/j.neo.2017.09.002","volume":"19","author":"B Oronsky","year":"2017","unstructured":"Oronsky B, Ma PC, Morgensztern D, Carter CA. Nothing But NET: A Review of Neuroendocrine Tumors and Carcinomas. Neoplasia. 2017;19(12):991\u20131002.","journal-title":"Neoplasia"},{"issue":"4","key":"2697_CR2","doi-asserted-by":"publisher","first-page":"589","DOI":"10.1002\/cncr.29099","volume":"121","author":"J Hallet","year":"2015","unstructured":"Hallet J, Law CH, Cukier M, Saskin R, Liu N, Singh S. Exploring the rising incidence of neuroendocrine tumors: a population-based analysis of epidemiology, metastatic presentation, and outcomes. Cancer. 2015;121(4):589\u201397.","journal-title":"Cancer"},{"issue":"6","key":"2697_CR3","first-page":"471","volume":"68","author":"M Cives","year":"2018","unstructured":"Cives M, Strosberg JR. Gastroenteropancreatic Neuroendocrine Tumors. CA Cancer J Clin. 2018;68(6):471\u201387.","journal-title":"CA Cancer J Clin"},{"issue":"10","key":"2697_CR4","doi-asserted-by":"publisher","first-page":"1335","DOI":"10.1001\/jamaoncol.2017.0589","volume":"3","author":"A Dasari","year":"2017","unstructured":"Dasari A, Shen C, Halperin D, Zhao B, Zhou S, Xu Y, et al. Trends in the Incidence, Prevalence, and Survival Outcomes in Patients With Neuroendocrine Tumors in the United States. JAMA Oncol. 2017;3(10):1335\u201342.","journal-title":"JAMA Oncol"},{"key":"2697_CR5","doi-asserted-by":"crossref","unstructured":"Bevere M, Masetto F, Carazzolo ME, Bettega A, Gkountakos A, Scarpa A et al. An overview of circulating biomarkers in neuroendocrine neoplasms: a clinical guide. Diagnostics (Basel). 2023;13(17):2820.","DOI":"10.3390\/diagnostics13172820"},{"issue":"2","key":"2697_CR6","doi-asserted-by":"publisher","first-page":"506","DOI":"10.1210\/er.2018-00160","volume":"40","author":"A Mafficini","year":"2019","unstructured":"Mafficini A, Scarpa A. Genetics and Epigenetics of Gastroenteropancreatic Neuroendocrine Neoplasms. Endocr Rev. 2019;40(2):506\u201336.","journal-title":"Endocr Rev"},{"issue":"2","key":"2697_CR7","doi-asserted-by":"publisher","first-page":"91","DOI":"10.1007\/s12022-024-09807-2","volume":"35","author":"S Uccella","year":"2024","unstructured":"Uccella S. Molecular Classification of Gastrointestinal and Pancreatic Neuroendocrine Neoplasms: Are We Ready for That? Endocr Pathol. 2024;35(2):91\u2013106.","journal-title":"Endocr Pathol"},{"issue":"5","key":"2697_CR8","doi-asserted-by":"publisher","first-page":"101794","DOI":"10.1016\/j.beem.2023.101794","volume":"37","author":"N Fazio","year":"2023","unstructured":"Fazio N, La Salvia A. Precision medicine in gastroenteropancreatic neuroendocrine neoplasms: Where are we in 2023? Best Pract Res Clin Endocrinol Metab. 2023;37(5):101794.","journal-title":"Best Pract Res Clin Endocrinol Metab"},{"issue":"1","key":"2697_CR9","doi-asserted-by":"publisher","first-page":"115","DOI":"10.1007\/s12022-022-09708-2","volume":"33","author":"G Rindi","year":"2022","unstructured":"Rindi G, Mete O, Uccella S, Basturk O, La Rosa S, Brosens LAA, et al. Overview of the 2022 WHO Classification of Neuroendocrine Neoplasms. Endocr Pathol. 2022;33(1):115\u201354.","journal-title":"Endocr Pathol"},{"issue":"10","key":"2697_CR10","doi-asserted-by":"publisher","first-page":"7001","DOI":"10.1245\/s10434-024-15632-y","volume":"31","author":"OC Eren","year":"2024","unstructured":"Eren OC, Bagci P, Balci S, Ohike N, Saka B, Sokmensuer C, et al. Subgrading of G2 Pancreatic Neuroendocrine Tumors as 2A (Ki67 3% to <\u200910%) Versus 2B (10% to = 20%) Identifies Behaviorally Distinct Subsets in Keeping with the Evolving Management Protocols<\/at. Ann Surg Oncol. 2024;31(10):7001\u201311.","journal-title":"Ann Surg Oncol"},{"issue":"1","key":"2697_CR11","doi-asserted-by":"publisher","first-page":"24","DOI":"10.1007\/s12022-025-09866-z","volume":"36","author":"AL Kiemen","year":"2025","unstructured":"Kiemen AL, Young ED, Blackford AL, Wu P, Burkhart RA, Burns WR, et al. Prognostic Features in Surgically Resected Well-Differentiated Pancreatic Neuroendocrine Tumors: an Analysis of 904 Patients with 7882 Person-Years of Follow-Up. Endocr Pathol. 2025;36(1):24.","journal-title":"Endocr Pathol"},{"key":"2697_CR12","doi-asserted-by":"crossref","unstructured":"Podrascanin V, Ammann M, Gudmundsdottir H, Dong Y, Santol J, Pereyra D et al. The paradox of Grade 2 pancreatic neuroendocrine tumors: G2a\/G2b subdivision in patients with and without liver metastases: a retrospective single-center analysis. Ann Surg Oncol. 2026;33(4):3425\u201334.","DOI":"10.1245\/s10434-025-18887-1"},{"issue":"1","key":"2697_CR13","doi-asserted-by":"publisher","first-page":"85","DOI":"10.1159\/000445165","volume":"104","author":"M Milione","year":"2017","unstructured":"Milione M, Maisonneuve P, Spada F, Pellegrinelli A, Spaggiari P, Albarello L, et al. The Clinicopathologic Heterogeneity of Grade 3 Gastroenteropancreatic Neuroendocrine Neoplasms: Morphological Differentiation and Proliferation Identify Different Prognostic Categories. Neuroendocrinology. 2017;104(1):85\u201393.","journal-title":"Neuroendocrinology"},{"issue":"1","key":"2697_CR14","doi-asserted-by":"publisher","first-page":"152","DOI":"10.1093\/annonc\/mds276","volume":"24","author":"H Sorbye","year":"2013","unstructured":"Sorbye H, Welin S, Langer SW, Vestermark LW, Holt N, Osterlund P, et al. Predictive and prognostic factors for treatment and survival in 305 patients with advanced gastrointestinal neuroendocrine carcinoma (WHO G3): the NORDIC NEC study. Ann Oncol. 2013;24(1):152\u201360.","journal-title":"Ann Oncol"},{"issue":"3","key":"2697_CR15","doi-asserted-by":"publisher","first-page":"683","DOI":"10.1016\/j.ecl.2018.05.001","volume":"47","author":"H Sorbye","year":"2018","unstructured":"Sorbye H, Baudin E, Perren A. The Problem of High-Grade Gastroenteropancreatic Neuroendocrine Neoplasms: Well-Differentiated Neuroendocrine Tumors, Neuroendocrine Carcinomas, and Beyond. Endocrinol Metab Clin North Am. 2018;47(3):683\u201398.","journal-title":"Endocrinol Metab Clin North Am"},{"issue":"1","key":"2697_CR16","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1007\/s00428-025-04336-7","volume":"488","author":"D Bahceci","year":"2026","unstructured":"Bahceci D, Adsay V, Basturk O. Differentiating well-differentiated neuroendocrine tumors grade 3 from poorly differentiated neuroendocrine carcinomas and adenocarcinoma with neuroendocrine differentiation: a comprehensive review. Virchows Arch. 2026;488(1):45\u201364.","journal-title":"Virchows Arch"},{"issue":"32","key":"2697_CR17","doi-asserted-by":"publisher","first-page":"9512","DOI":"10.3748\/wjg.v21.i32.9512","volume":"21","author":"JM Cloyd","year":"2015","unstructured":"Cloyd JM, Poultsides GA. Non-functional neuroendocrine tumors of the pancreas: Advances in diagnosis and management. World J Gastroenterol. 2015;21(32):9512\u201325.","journal-title":"World J Gastroenterol"},{"key":"2697_CR18","doi-asserted-by":"crossref","unstructured":"Bevere M, Gkountakos A, Martelli FM, Scarpa A, Luchini C, Simbolo M. An insight on functioning pancreatic neuroendocrine neoplasms. Biomedicines. 2023;11(2):303.","DOI":"10.3390\/biomedicines11020303"},{"issue":"1","key":"2697_CR19","doi-asserted-by":"publisher","first-page":"224","DOI":"10.1016\/j.pan.2020.11.020","volume":"21","author":"A Nie\u00dfen","year":"2021","unstructured":"Nie\u00dfen A, Schimmack S, Weber TF, Mayer P, Bergmann F, Hinz U, et al. Presentation and outcome of mixed neuroendocrine non-neuroendocrine neoplasms of the pancreas. Pancreatology. 2021;21(1):224\u201335.","journal-title":"Pancreatology"},{"issue":"3","key":"2697_CR20","doi-asserted-by":"publisher","first-page":"239","DOI":"10.1007\/s12022-020-09628-z","volume":"31","author":"Y Xue","year":"2020","unstructured":"Xue Y, Reid MD, Pehlivanoglu B, Obeng RC, Jiang H, Memis B, et al. Morphologic Variants of Pancreatic Neuroendocrine Tumors: Clinicopathologic Analysis and Prognostic Stratification. Endocr Pathol. 2020;31(3):239\u201353.","journal-title":"Endocr Pathol"},{"issue":"2","key":"2697_CR21","doi-asserted-by":"publisher","first-page":"225","DOI":"10.1111\/his.12535","volume":"66","author":"A Johnson","year":"2015","unstructured":"Johnson A, Wright JP, Zhao Z, Komaya T, Parikh A, Merchant N, et al. Cadherin 17 is frequently expressed by \u2018sclerosing variant\u2019 pancreatic neuroendocrine tumour. Histopathology. 2015;66(2):225\u201333.","journal-title":"Histopathology"},{"issue":"11","key":"2697_CR22","doi-asserted-by":"publisher","first-page":"1713","DOI":"10.1038\/s41379-022-01110-x","volume":"35","author":"T Depoilly","year":"2022","unstructured":"Depoilly T, Leroux R, Andrade D, Nicolle R, Dioguardi Burgio M, Marinoni I, et al. Immunophenotypic and molecular characterization of pancreatic neuroendocrine tumors producing serotonin. Mod Pathol. 2022;35(11):1713\u201322.","journal-title":"Mod Pathol"},{"issue":"6","key":"2697_CR23","doi-asserted-by":"publisher","first-page":"777","DOI":"10.1038\/s41379-021-00995-4","volume":"35","author":"OC Taskin","year":"2022","unstructured":"Taskin OC, Reid MD, Bagci P, Balci S, Armutlu A, Demirtas D, et al. Infiltration pattern predicts metastasis and progression better than the T-stage and grade in pancreatic neuroendocrine tumors: a proposal for a novel infiltration-based morphologic grading. Mod Pathol. 2022;35(6):777\u201385.","journal-title":"Mod Pathol"},{"issue":"1","key":"2697_CR24","doi-asserted-by":"publisher","first-page":"2","DOI":"10.1007\/s12022-025-09846-3","volume":"36","author":"S Koc","year":"2025","unstructured":"Koc S, Eren OC, Esmer R, Kasapoglu FU, Saka B, Taskin OC, et al. Deep Learning Enabled Scoring of Pancreatic Neuroendocrine Tumors Based on Cancer Infiltration Patterns. Endocr Pathol. 2025;36(1):2.","journal-title":"Endocr Pathol"},{"issue":"12","key":"2697_CR25","doi-asserted-by":"publisher","first-page":"1373","DOI":"10.1016\/S0046-8177(97)90226-4","volume":"28","author":"O Kaufmann","year":"1997","unstructured":"Kaufmann O, Georgi T, Dietel M. Utility of 123C3 monoclonal antibody against CD56 (NCAM) for the diagnosis of small cell carcinomas on paraffin sections. Hum Pathol. 1997;28(12):1373\u201378.","journal-title":"Hum Pathol"},{"issue":"3","key":"2697_CR26","doi-asserted-by":"publisher","first-page":"236","DOI":"10.1093\/ajcp\/aqx071","volume":"148","author":"JE Love","year":"2017","unstructured":"Love JE, Thompson K, Kilgore MR, Westerhoff M, Murphy CE, Papanicolau-Sengos A, et al. CD200 Expression in Neuroendocrine Neoplasms. Am J Clin Pathol. 2017;148(3):236\u201342.","journal-title":"Am J Clin Pathol"},{"issue":"1","key":"2697_CR27","doi-asserted-by":"publisher","first-page":"754","DOI":"10.1007\/s12672-025-02576-2","volume":"16","author":"S Kim","year":"2025","unstructured":"Kim S, Seo J, Shin Y, Kim M. Expression of insulinoma-associated protein 1 (INSM1) in gastric neuroendocrine and non-neuroendocrine neoplasms. Discov Oncol. 2025;16(1):754.","journal-title":"Discov Oncol"},{"issue":"3","key":"2697_CR28","doi-asserted-by":"publisher","first-page":"196","DOI":"10.1159\/000457956","volume":"105","author":"A Perren","year":"2017","unstructured":"Perren A, Couvelard A, Scoazec JY, Costa F, Borbath I, Delle Fave G, et al. ENETS Consensus Guidelines for the Standards of Care in Neuroendocrine Tumors: Pathology: Diagnosis and Prognostic Stratification. Neuroendocrinology. 2017;105(3):196\u2013200.","journal-title":"Neuroendocrinology"},{"issue":"1","key":"2697_CR29","doi-asserted-by":"publisher","first-page":"168","DOI":"10.1111\/his.13408","volume":"72","author":"AD Singhi","year":"2018","unstructured":"Singhi AD, Klimstra DS. Well-differentiated pancreatic neuroendocrine tumours (PanNETs) and poorly differentiated pancreatic neuroendocrine carcinomas (PanNECs): concepts, issues and a practical diagnostic approach to high-grade (G3) cases. Histopathology. 2018;72(1):168\u201377.","journal-title":"Histopathology"},{"issue":"5","key":"2697_CR30","doi-asserted-by":"publisher","first-page":"649","DOI":"10.1530\/ERC-13-0027","volume":"20","author":"FL Velayoudom-Cephise","year":"2013","unstructured":"Velayoudom-Cephise FL, Duvillard P, Foucan L, Hadoux J, Chougnet CN, Leboulleux S, et al. Are G3 ENETS neuroendocrine neoplasms heterogeneous? Endocr Relat Cancer. 2013;20(5):649\u201357.","journal-title":"Endocr Relat Cancer"},{"key":"2697_CR31","doi-asserted-by":"crossref","unstructured":"Frizziero M, Durand A, Taboada RG, Zaninotto E, Luchini C, Chakrabarty B et al. Is the morphological subtype of extra-pulmonary neuroendocrine carcinoma clinically relevant? Cancers. (Basel). 2021;13(16):4152.","DOI":"10.3390\/cancers13164152"},{"issue":"2","key":"2697_CR32","doi-asserted-by":"publisher","first-page":"173","DOI":"10.1097\/PAS.0b013e3182417d36","volume":"36","author":"S Yachida","year":"2012","unstructured":"Yachida S, Vakiani E, White CM, Zhong Y, Saunders T, Morgan R, et al. Small cell and large cell neuroendocrine carcinomas of the pancreas are genetically similar and distinct from well-differentiated pancreatic neuroendocrine tumors. Am J Surg Pathol. 2012;36(2):173\u201384.","journal-title":"Am J Surg Pathol"},{"issue":"3","key":"2697_CR33","doi-asserted-by":"publisher","first-page":"692","DOI":"10.1158\/2159-8290.CD-21-0669","volume":"12","author":"S Yachida","year":"2022","unstructured":"Yachida S, Totoki Y, Noe M, Nakatani Y, Horie M, Kawasaki K, et al. Comprehensive Genomic Profiling of Neuroendocrine Carcinomas of the Gastrointestinal System. Cancer Discov. 2022;12(3):692\u2013711.","journal-title":"Cancer Discov"},{"issue":"5","key":"2697_CR34","doi-asserted-by":"publisher","first-page":"583","DOI":"10.1530\/ERC-17-0557","volume":"25","author":"M Milione","year":"2018","unstructured":"Milione M, Maisonneuve P, Pellegrinelli A, Grillo F, Albarello L, Spaggiari P, et al. Ki67 proliferative index of the neuroendocrine component drives MANEC prognosis. Endocr Relat Cancer. 2018;25(5):583\u201393.","journal-title":"Endocr Relat Cancer"},{"issue":"7","key":"2697_CR35","doi-asserted-by":"publisher","first-page":"485","DOI":"10.1111\/pin.13105","volume":"71","author":"AS Akki","year":"2021","unstructured":"Akki AS, Liu X, Clapp WL, Starostik P, Newsom KJ, Hughes SJ, et al. Mixed acinar-neuroendocrine carcinoma with amphicrine features of the pancreas: Two rare cases with diffuse co-expression of acinar and neuroendocrine markers. Pathol Int. 2021;71(7):485\u20137.","journal-title":"Pathol Int"},{"issue":"12","key":"2697_CR36","first-page":"1381","volume":"31","author":"M Jakobsen","year":"2016","unstructured":"Jakobsen M, Kloppel G, Detlefsen S. Mixed acinar-neuroendocrine carcinoma of the pancreas: a case report and a review. Histol Histopathol. 2016;31(12):1381\u20138.","journal-title":"Histol Histopathol"},{"issue":"6","key":"2697_CR37","doi-asserted-by":"publisher","first-page":"712","DOI":"10.1038\/s41379-022-01055-1","volume":"35","author":"C Luchini","year":"2022","unstructured":"Luchini C, Pantanowitz L, Adsay V, Asa SL, Antonini P, Girolami I, et al. Ki-67 assessment of pancreatic neuroendocrine neoplasms: Systematic review and meta-analysis of manual vs. digital pathology scoring. Mod Pathol. 2022;35(6):712\u201320.","journal-title":"Mod Pathol"},{"key":"2697_CR38","doi-asserted-by":"crossref","unstructured":"Merola E, Fanciulli G, Pes GM, Dore MP. Artificial intelligence in the diagnosis of gastro-entero-pancreatic neuroendocrine neoplasms: Potential benefits and current limitations. J Neuroendocrinol. 2025;37(11):e70087.","DOI":"10.1111\/jne.70087"},{"issue":"6","key":"2697_CR39","doi-asserted-by":"publisher","first-page":"558","DOI":"10.1111\/j.1399-0004.2011.01805.x","volume":"82","author":"AM Larson","year":"2012","unstructured":"Larson AM, Hedgire SS, Deshpande V, Stemmer-Rachamimov AO, Harisinghani MG, Ferrone CR, et al. Pancreatic neuroendocrine tumors in patients with tuberous sclerosis complex. Clin Genet. 2012;82(6):558\u201363.","journal-title":"Clin Genet"},{"issue":"1","key":"2697_CR40","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1007\/s00247-016-3701-0","volume":"47","author":"G Koc","year":"2017","unstructured":"Koc G, Sugimoto S, Kuperman R, Kammen BF, Karakas SP. Pancreatic tumors in children and young adults with tuberous sclerosis complex. Pediatr Radiol. 2017;47(1):39\u201345.","journal-title":"Pediatr Radiol"},{"issue":"2","key":"2697_CR41","doi-asserted-by":"publisher","first-page":"L1","DOI":"10.1530\/ERC-17-0286","volume":"25","author":"PF Asprino","year":"2018","unstructured":"Asprino PF, Linck RDM, Cesar J, Freitas FP, Koyama FC, Riechelmann RSP, et al. TSC2 rare germline variants in non-tuberous sclerosis patients with neuroendocrine neoplasias. Endocr Relat Cancer. 2018;25(2):L1\u20135.","journal-title":"Endocr Relat Cancer"},{"issue":"10","key":"2697_CR42","doi-asserted-by":"publisher","first-page":"1532","DOI":"10.1038\/s41379-018-0082-y","volume":"31","author":"M Noe","year":"2018","unstructured":"Noe M, Pea A, Luchini C, Felsenstein M, Barbi S, Bhaijee F, et al. Whole-exome sequencing of duodenal neuroendocrine tumors in patients with neurofibromatosis type 1. Mod Pathol. 2018;31(10):1532\u20138.","journal-title":"Mod Pathol"},{"issue":"9","key":"2697_CR43","doi-asserted-by":"publisher","first-page":"783","DOI":"10.1530\/ERC-18-0100","volume":"25","author":"T Krauss","year":"2018","unstructured":"Krauss T, Ferrara AM, Links TP, Wellner U, Bancos I, Kvachenyuk A, et al. Preventive medicine of von Hippel-Lindau disease-associated pancreatic neuroendocrine tumors. Endocr Relat Cancer. 2018;25(9):783\u201393.","journal-title":"Endocr Relat Cancer"},{"issue":"7","key":"2697_CR44","doi-asserted-by":"publisher","first-page":"609","DOI":"10.1159\/000511791","volume":"111","author":"B Niederle","year":"2021","unstructured":"Niederle B, Selberherr A, Bartsch DK, Brandi ML, Doherty GM, Falconi M, et al. Multiple Endocrine Neoplasia Type 1 and the Pancreas: Diagnosis and Treatment of Functioning and Non-Functioning Pancreatic and Duodenal Neuroendocrine Neoplasia within the MEN1 Syndrome - An International Consensus Statement. Neuroendocrinology. 2021;111(7):609\u201330.","journal-title":"Neuroendocrinology"},{"key":"2697_CR45","doi-asserted-by":"publisher","first-page":"e2400221","DOI":"10.1200\/PO.24.00221","volume":"8","author":"A De Jesus-Acosta","year":"2024","unstructured":"De Jesus-Acosta A, Mohindroo C. Genomic Landscape of Pancreatic Neuroendocrine Tumors and Implications for Clinical Practice. JCO Precis Oncol. 2024;8:e2400221.","journal-title":"JCO Precis Oncol"},{"issue":"2","key":"2697_CR46","doi-asserted-by":"publisher","first-page":"353","DOI":"10.1210\/jc.2015-3684","volume":"101","author":"V Neychev","year":"2016","unstructured":"Neychev V, Sadowski SM, Zhu J, Allgaeuer M, Kilian K, Meltzer P, et al. Neuroendocrine Tumor of the Pancreas as a Manifestation of Cowden Syndrome: A Case Report. J Clin Endocrinol Metab. 2016;101(2):353\u20138.","journal-title":"J Clin Endocrinol Metab"},{"issue":"6","key":"2697_CR47","doi-asserted-by":"publisher","first-page":"580","DOI":"10.4158\/EP-2018-0603","volume":"25","author":"A Tirosh","year":"2019","unstructured":"Tirosh A, Killian JK, Zhu YJ, Petersen D, Walling J, Mor-Cohen R, et al. Oncogene Panel Sequencing Analysis Identifies Candidate Actionable Genes in Advanced Well-Differentiated Gastroenteropancreatic Neuroendocrine Tumors. Endocr Pract. 2019;25(6):580\u20138.","journal-title":"Endocr Pract"},{"issue":"3","key":"2697_CR48","doi-asserted-by":"publisher","first-page":"237","DOI":"10.1007\/s12022-019-9569-4","volume":"30","author":"M Szybowska","year":"2019","unstructured":"Szybowska M, Mete O, Weber E, Silver J, Kim RH. Neuroendocrine Neoplasms Associated with Germline Pathogenic Variants in the Homologous Recombination Pathway. Endocr Pathol. 2019;30(3):237\u201345.","journal-title":"Endocr Pathol"},{"key":"2697_CR49","doi-asserted-by":"publisher","first-page":"1024108","DOI":"10.3389\/fendo.2022.1024108","volume":"13","author":"RD Vallera","year":"2022","unstructured":"Vallera RD, Ding Y, Hatanpaa KJ, Bishop JA, Mirfakhraee S, Alli AA, et al. Case report: Two sisters with a germline CHEK2 variant and distinct endocrine neoplasias. Front Endocrinol (Lausanne). 2022;13:1024108.","journal-title":"Front Endocrinol (Lausanne)"},{"issue":"10","key":"2697_CR50","doi-asserted-by":"publisher","first-page":"1677","DOI":"10.1016\/j.humpath.2011.12.012","volume":"43","author":"Y Karamurzin","year":"2012","unstructured":"Karamurzin Y, Zeng Z, Stadler ZK, Zhang L, Ouansafi I, Al-Ahmadie HA, et al. Unusual DNA mismatch repair-deficient tumors in Lynch syndrome: a report of new cases and review of the literature. Hum Pathol. 2012;43(10):1677\u201387.","journal-title":"Hum Pathol"},{"issue":"5","key":"2697_CR51","doi-asserted-by":"publisher","first-page":"E73","DOI":"10.21037\/jgo.2017.07.02","volume":"8","author":"A Serracant Barrera","year":"2017","unstructured":"Serracant Barrera A, Serra Pla S, Blazquez Mana CM, Salas RC, Garcia Monforte N, Bejarano Gonzalez N, et al. Pancreatic non-functioning neuroendocrine tumor: a new entity genetically related to Lynch syndrome. J Gastrointest Oncol. 2017;8(5):E73\u20139.","journal-title":"J Gastrointest Oncol"},{"issue":"9","key":"2697_CR52","doi-asserted-by":"publisher","first-page":"1297","DOI":"10.1097\/PAS.0000000000001314","volume":"43","author":"M Noe","year":"2019","unstructured":"Noe M, Hackeng WM, de Leng WWJ, Vergeer M, Vleggaar FP, Morsink FHM, et al. Well-differentiated Pancreatic Neuroendocrine Tumor in a Patient With Familial Atypical Multiple Mole Melanoma Syndrome (FAMMM). Am J Surg Pathol. 2019;43(9):1297\u2013302.","journal-title":"Am J Surg Pathol"},{"key":"2697_CR53","doi-asserted-by":"publisher","first-page":"264","DOI":"10.1186\/s13104-015-1235-4","volume":"8","author":"TP Potjer","year":"2015","unstructured":"Potjer TP, van der Stoep N, Houwing-Duistermaat JJ, Konings IC, Aalfs CM, van den Akker PC, et al. Pancreatic cancer-associated gene polymorphisms in a nation-wide cohort of p16-Leiden germline mutation carriers; a case-control study. BMC Res Notes. 2015;8:264.","journal-title":"BMC Res Notes"},{"issue":"1","key":"2697_CR54","doi-asserted-by":"publisher","first-page":"256","DOI":"10.1186\/s12885-020-06723-6","volume":"20","author":"JG Aversa","year":"2020","unstructured":"Aversa JG, De Abreu FB, Yano S, Xi L, Hadley DW, Manoli I, et al. The first pancreatic neuroendocrine tumor in Li-Fraumeni syndrome: a case report. BMC Cancer. 2020;20(1):256.","journal-title":"BMC Cancer"},{"issue":"10","key":"2697_CR55","doi-asserted-by":"publisher","first-page":"E1386","DOI":"10.1210\/jc.2015-2689","volume":"100","author":"ND Niemeijer","year":"2015","unstructured":"Niemeijer ND, Papathomas TG, Korpershoek E, de Krijger RR, Oudijk L, Morreau H, et al. Succinate Dehydrogenase (SDH)-Deficient Pancreatic Neuroendocrine Tumor Expands the SDH-Related Tumor Spectrum. J Clin Endocrinol Metab. 2015;100(10):E1386\u201393.","journal-title":"J Clin Endocrinol Metab"},{"issue":"5","key":"2697_CR56","doi-asserted-by":"publisher","first-page":"1027","DOI":"10.1073\/pnas.1712262115","volume":"115","author":"D Iacovazzo","year":"2018","unstructured":"Iacovazzo D, Flanagan SE, Walker E, Quezado R, de Sousa Barros FA, Caswell R, et al. MAFA missense mutation causes familial insulinomatosis and diabetes mellitus. Proc Natl Acad Sci U S A. 2018;115(5):1027\u201332.","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"5","key":"2697_CR57","doi-asserted-by":"publisher","first-page":"E783","DOI":"10.1210\/jc.2014-4405","volume":"100","author":"B Sipos","year":"2015","unstructured":"Sipos B, Sperveslage J, Anlauf M, Hoffmeister M, Henopp T, Buch S, et al. Glucagon cell hyperplasia and neoplasia with and without glucagon receptor mutations. J Clin Endocrinol Metab. 2015;100(5):E783\u20138.","journal-title":"J Clin Endocrinol Metab"},{"issue":"9","key":"2697_CR58","doi-asserted-by":"publisher","first-page":"975","DOI":"10.5858\/arpa.2022-0417-RA","volume":"148","author":"C Luchini","year":"2024","unstructured":"Luchini C, Scarpa A. Neoplastic Progression in Neuroendocrine Neoplasms of the Pancreas. Arch Pathol Lab Med. 2024;148(9):975\u20139.","journal-title":"Arch Pathol Lab Med"},{"issue":"7643","key":"2697_CR59","doi-asserted-by":"publisher","first-page":"65","DOI":"10.1038\/nature21063","volume":"543","author":"A Scarpa","year":"2017","unstructured":"Scarpa A, Chang DK, Nones K, Corbo V, Patch AM, Bailey P, et al. Whole-genome landscape of pancreatic neuroendocrine tumours. Nature. 2017;543(7643):65\u201371.","journal-title":"Nature"},{"key":"2697_CR60","doi-asserted-by":"crossref","unstructured":"Raj N, Shah R, Stadler Z, Mukherjee S, Chou J, Untch B et al. Real-Time Genomic Characterization of Metastatic Pancreatic Neuroendocrine Tumors Has Prognostic Implications and Identifies Potential Germline Actionability. JCO Precis Oncol. 2018;2018:PO.17.00267.","DOI":"10.1200\/PO.17.00267"},{"key":"2697_CR61","doi-asserted-by":"crossref","unstructured":"Riechelmann RP, Donadio MDS, Jesus VHF, de Carvalho NA, Santiago KM, Barros MJ et al. Germline pathogenic variants in patients with early-onset neuroendocrine neoplasms. Endocr Relat Cancer. 2023;30(6):e220258.","DOI":"10.1530\/ERC-22-0258"},{"key":"2697_CR62","doi-asserted-by":"crossref","unstructured":"Venizelos A, Sorbye H, Elvebakken H, Perren A, Lothe IMB, Couvelard A et al. Germline pathogenic variants in patients with high-grade gastroenteropancreatic neuroendocrine neoplasms. Endocr Relat Cancer. 2023;30(10):e230057.","DOI":"10.1530\/ERC-23-0057"},{"issue":"7","key":"2697_CR63","doi-asserted-by":"publisher","first-page":"335","DOI":"10.1158\/1940-6207.CAPR-23-0483","volume":"17","author":"C Mohindroo","year":"2024","unstructured":"Mohindroo C, Baydogan S, Agarwal P, Wright RD, Prakash LR, Mork ME, et al. Germline Testing Identifies Pathogenic\/Likely Pathogenic Variants in Patients with Pancreatic Neuroendocrine Tumors. Cancer Prev Res (Phila). 2024;17(7):335\u201342.","journal-title":"Cancer Prev Res (Phila)"},{"issue":"19","key":"2697_CR64","doi-asserted-by":"publisher","first-page":"2927","DOI":"10.1002\/cncr.34896","volume":"129","author":"AB Daniels","year":"2023","unstructured":"Daniels AB, Tirosh A, Huntoon K, Mehta GU, Spiess PE, Friedman DL, et al. Guidelines for surveillance of patients with von Hippel-Lindau disease: Consensus statement of the International VHL Surveillance Guidelines Consortium and VHL Alliance. Cancer. 2023;129(19):2927\u201340.","journal-title":"Cancer"},{"issue":"8","key":"2697_CR65","doi-asserted-by":"publisher","first-page":"e13318","DOI":"10.1111\/jne.13318","volume":"35","author":"J Hofland","year":"2023","unstructured":"Hofland J, Falconi M, Christ E, Castano JP, Faggiano A, Lamarca A, et al. European Neuroendocrine Tumor Society 2023 guidance paper for functioning pancreatic neuroendocrine tumour syndromes. J Neuroendocrinol. 2023;35(8):e13318.","journal-title":"J Neuroendocrinol"},{"issue":"1","key":"2697_CR66","doi-asserted-by":"publisher","first-page":"e13468","DOI":"10.1111\/jne.13468","volume":"37","author":"CRC Pieterman","year":"2025","unstructured":"Pieterman CRC, Grozinsky-Glasberg S, O\u2019Toole D, Howe JR, Ambrosini V, Belli SH, et al. Screening and surveillance practices for Multiple Endocrine Neoplasia type 1-related Neuroendocrine Tumours in European Neuroendocrine Tumor Society Centers of Excellence (ENETS CoE)-An ENETS MEN1 task force questionnaire study. J Neuroendocrinol. 2025;37(1):e13468.","journal-title":"J Neuroendocrinol"},{"key":"2697_CR67","doi-asserted-by":"publisher","first-page":"681013","DOI":"10.3389\/fendo.2021.681013","volume":"12","author":"P Soczomski","year":"2021","unstructured":"Soczomski P, Jurecka-Lubieniecka B, Krzywon A, Cortez AJ, Zgliczynski S, Rogozik N, et al. A Direct Comparison of Patients With Hereditary and Sporadic Pancreatic Neuroendocrine Tumors: Evaluation of Clinical Course, Prognostic Factors and Genotype-Phenotype Correlations. Front Endocrinol (Lausanne). 2021;12:681013.","journal-title":"Front Endocrinol (Lausanne)"},{"issue":"4","key":"2697_CR68","doi-asserted-by":"publisher","first-page":"645","DOI":"10.21037\/jgo.2019.01.33","volume":"10","author":"JE Nunez","year":"2019","unstructured":"Nunez JE, Donadio M, Filho DR, Rego JF, Barros M, Formiga MN, et al. The efficacy of everolimus and sunitinib in patients with sporadic or germline mutated metastatic pancreatic neuroendocrine tumors. J Gastrointest Oncol. 2019;10(4):645\u201351.","journal-title":"J Gastrointest Oncol"},{"issue":"7","key":"2697_CR69","doi-asserted-by":"publisher","first-page":"844","DOI":"10.1016\/j.annonc.2020.03.304","volume":"31","author":"M Pavel","year":"2020","unstructured":"Pavel M, Oberg K, Falconi M, Krenning EP, Sundin A, Perren A, et al. Gastroenteropancreatic neuroendocrine neoplasms: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2020;31(7):844\u201360.","journal-title":"Ann Oncol"},{"issue":"Suppl","key":"2697_CR70","first-page":"e255012","volume":"23","author":"EK Bergsland","year":"2025","unstructured":"Bergsland EK. Management of Advanced Gastroenteropancreatic Neuroendocrine Tumors. Natl Compr Canc Netw. 2025;23(Suppl):e255012.","journal-title":"Natl Compr Canc Netw"},{"key":"2697_CR71","doi-asserted-by":"publisher","first-page":"112","DOI":"10.1016\/j.semcancer.2025.03.005","volume":"112","author":"M Tacelli","year":"2025","unstructured":"Tacelli M, Gentiluomo M, Biamonte P, Castano JP, Berkovic MC, Cives M, et al. Pancreatic neuroendocrine neoplasms (pNENs): Genetic and environmental biomarkers for risk of occurrence and prognosis. Semin Cancer Biol. 2025;112:112\u201325.","journal-title":"Semin Cancer Biol"},{"key":"2697_CR72","doi-asserted-by":"publisher","first-page":"39565","DOI":"10.1038\/srep39565","volume":"6","author":"D Campa","year":"2016","unstructured":"Campa D, Capurso G, Pastore M, Talar-Wojnarowska R, Milanetto AC, Landoni L, et al. Common germline variants within the CDKN2A\/2B region affect risk of pancreatic neuroendocrine tumors. Sci Rep. 2016;6:39565.","journal-title":"Sci Rep"},{"issue":"12","key":"2697_CR73","doi-asserted-by":"publisher","first-page":"1168","DOI":"10.1159\/000524659","volume":"112","author":"M Gentiluomo","year":"2022","unstructured":"Gentiluomo M, Capurso G, Morelli L, Ermini S, Pasquali C, Latiano A, et al. Genetically Determined Telomere Length Is Associated with Pancreatic Neuroendocrine Neoplasms Onset. Neuroendocrinology. 2022;112(12):1168\u201376.","journal-title":"Neuroendocrinology"},{"issue":"8","key":"2697_CR74","doi-asserted-by":"publisher","first-page":"911","DOI":"10.1038\/ng.3341","volume":"47","author":"EJ Childs","year":"2015","unstructured":"Childs EJ, Mocci E, Campa D, Bracci PM, Gallinger S, Goggins M, et al. Common variation at 2p13.3, 3q29, 7p13 and 17q25.1 associated with susceptibility to pancreatic cancer. Nat Genet. 2015;47(8):911\u20136.","journal-title":"Nat Genet"},{"issue":"9","key":"2697_CR75","doi-asserted-by":"publisher","first-page":"994","DOI":"10.1038\/ng.3052","volume":"46","author":"BM Wolpin","year":"2014","unstructured":"Wolpin BM, Rizzato C, Kraft P, Kooperberg C, Petersen GM, Wang Z, et al. Genome-wide association study identifies multiple susceptibility loci for pancreatic cancer. Nat Genet. 2014;46(9):994\u20131000.","journal-title":"Nat Genet"},{"issue":"9","key":"2697_CR76","doi-asserted-by":"publisher","first-page":"986","DOI":"10.1038\/ng.429","volume":"41","author":"L Amundadottir","year":"2009","unstructured":"Amundadottir L, Kraft P, Stolzenberg-Solomon RZ, Fuchs CS, Petersen GM, Arslan AA, et al. Genome-wide association study identifies variants in the ABO locus associated with susceptibility to pancreatic cancer. Nat Genet. 2009;41(9):986\u201390.","journal-title":"Nat Genet"},{"issue":"3","key":"2697_CR77","doi-asserted-by":"publisher","first-page":"224","DOI":"10.1038\/ng.522","volume":"42","author":"GM Petersen","year":"2010","unstructured":"Petersen GM, Amundadottir L, Fuchs CS, Kraft P, Stolzenberg-Solomon RZ, Jacobs KB, et al. A genome-wide association study identifies pancreatic cancer susceptibility loci on chromosomes 13q22.1, 1q32.1 and 5p15.33. Nat Genet. 2010;42(3):224\u20138.","journal-title":"Nat Genet"},{"issue":"97","key":"2697_CR78","doi-asserted-by":"publisher","first-page":"36894","DOI":"10.18632\/oncotarget.26380","volume":"9","author":"P Jimenez-Fonseca","year":"2018","unstructured":"Jimenez-Fonseca P, Martin MN, Carmona-Bayonas A, Calvo A, Fernandez-Mateos J, Redrado M, et al. Biomarkers and polymorphisms in pancreatic neuroendocrine tumors treated with sunitinib. Oncotarget. 2018;9(97):36894\u2013905.","journal-title":"Oncotarget"},{"issue":"6021","key":"2697_CR79","doi-asserted-by":"publisher","first-page":"1199","DOI":"10.1126\/science.1200609","volume":"331","author":"Y Jiao","year":"2011","unstructured":"Jiao Y, Shi C, Edil BH, de Wilde RF, Klimstra DS, Maitra A, et al. DAXX\/ATRX, MEN1, and mTOR pathway genes are frequently altered in pancreatic neuroendocrine tumors. Science. 2011;331(6021):1199\u2013203.","journal-title":"Science"},{"issue":"2","key":"2697_CR80","doi-asserted-by":"publisher","first-page":"453","DOI":"10.1053\/j.gastro.2013.10.020","volume":"146","author":"I Marinoni","year":"2014","unstructured":"Marinoni I, Kurrer AS, Vassella E, Dettmer M, Rudolph T, Banz V, et al. Loss of DAXX and ATRX are associated with chromosome instability and reduced survival of patients with pancreatic neuroendocrine tumors. Gastroenterology. 2014;146(2):453\u201360. e5.","journal-title":"Gastroenterology"},{"issue":"5","key":"2697_CR81","doi-asserted-by":"publisher","first-page":"961","DOI":"10.1136\/gutjnl-2020-322595","volume":"71","author":"WM Hackeng","year":"2022","unstructured":"Hackeng WM, Brosens LAA, Kim JY, O\u2019Sullivan R, Sung YN, Liu TC, et al. Non-functional pancreatic neuroendocrine tumours: ATRX\/DAXX and alternative lengthening of telomeres (ALT) are prognostically independent from ARX\/PDX1 expression and tumour size. Gut. 2022;71(5):961\u201373.","journal-title":"Gut"},{"issue":"3","key":"2697_CR82","doi-asserted-by":"publisher","first-page":"566","DOI":"10.1097\/SLA.0000000000003022","volume":"271","author":"A Pea","year":"2020","unstructured":"Pea A, Yu J, Marchionni L, Noe M, Luchini C, Pulvirenti A, et al. Genetic Analysis of Small Well-differentiated Pancreatic Neuroendocrine Tumors Identifies Subgroups With Differing Risks of Liver Metastases. Ann Surg. 2020;271(3):566\u201373.","journal-title":"Ann Surg"},{"issue":"6","key":"2697_CR83","doi-asserted-by":"publisher","first-page":"1598","DOI":"10.1158\/1078-0432.CCR-16-1147","volume":"23","author":"JY Kim","year":"2017","unstructured":"Kim JY, Brosnan-Cashman JA, An S, Kim SJ, Song KB, Kim MS, et al. Alternative Lengthening of Telomeres in Primary Pancreatic Neuroendocrine Tumors Is Associated with Aggressive Clinical Behavior and Poor Survival. Clin Cancer Res. 2017;23(6):1598\u2013606.","journal-title":"Clin Cancer Res"},{"issue":"6041","key":"2697_CR84","doi-asserted-by":"publisher","first-page":"425","DOI":"10.1126\/science.1207313","volume":"333","author":"CM Heaphy","year":"2011","unstructured":"Heaphy CM, de Wilde RF, Jiao Y, Klein AP, Edil BH, Shi C, et al. Altered telomeres in tumors with ATRX and DAXX mutations. Science. 2011;333(6041):425.","journal-title":"Science"},{"issue":"9","key":"2697_CR85","doi-asserted-by":"publisher","first-page":"106","DOI":"10.1007\/s11912-021-01096-w","volume":"23","author":"C Luchini","year":"2021","unstructured":"Luchini C, Lawlor RT, Bersani S, Vicentini C, Paolino G, Mattiolo P, et al. Alternative Lengthening of Telomeres (ALT) in Pancreatic Neuroendocrine Tumors: Ready for Prime-Time in Clinical Practice? Curr Oncol Rep. 2021;23(9):106.","journal-title":"Curr Oncol Rep"},{"key":"2697_CR86","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1016\/j.humpath.2022.07.015","volume":"129","author":"CM Heaphy","year":"2022","unstructured":"Heaphy CM, Singhi AD. The diagnostic and prognostic utility of incorporating DAXX, ATRX, and alternative lengthening of telomeres to the evaluation of pancreatic neuroendocrine tumors. Hum Pathol. 2022;129:11\u201320.","journal-title":"Hum Pathol"},{"issue":"3","key":"2697_CR87","doi-asserted-by":"publisher","first-page":"100651","DOI":"10.1016\/j.modpat.2024.100651","volume":"38","author":"CM Heaphy","year":"2025","unstructured":"Heaphy CM, Patel S, Smith K, Wondisford AR, Lynskey ML, O\u2019Sullivan RJ, et al. Detection of Alternative Lengthening of Telomeres via Chromogenic In Situ Hybridization for the Prognostication of PanNETs and Other Neoplasms. Mod Pathol. 2025;38(3):100651.","journal-title":"Mod Pathol"},{"issue":"4","key":"2697_CR88","doi-asserted-by":"publisher","first-page":"e70003","DOI":"10.1111\/jne.70003","volume":"37","author":"H Gudmundsdottir","year":"2025","unstructured":"Gudmundsdottir H, Graham RP, Greipp PT, Habermann EB, Knudson RA, Brandt CA, et al. Alternative lengthening of telomeres and Ki-67 proliferation index provide complementary information on recurrence risk after resection of pancreatic neuroendocrine tumors. J Neuroendocrinol. 2025;37(4):e70003.","journal-title":"J Neuroendocrinol"},{"issue":"2","key":"2697_CR89","doi-asserted-by":"publisher","first-page":"600","DOI":"10.1158\/1078-0432.CCR-16-1113","volume":"23","author":"AD Singhi","year":"2017","unstructured":"Singhi AD, Liu TC, Roncaioli JL, Cao D, Zeh HJ, Zureikat AH, et al. Alternative Lengthening of Telomeres and Loss of DAXX\/ATRX Expression Predicts Metastatic Disease and Poor Survival in Patients with Pancreatic Neuroendocrine Tumors. Clin Cancer Res. 2017;23(2):600\u20139.","journal-title":"Clin Cancer Res"},{"issue":"1","key":"2697_CR90","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1007\/s12022-025-09848-1","volume":"36","author":"T van Veld","year":"2025","unstructured":"van Veld T, Hackeng BR, Luchini WM, Brosens C, Dreijerink LAA. Clinical Relevance of ATRX\/DAXX Gene Mutations and ALT in Functioning Pancreatic Neuroendocrine Tumors. Endocr Pathol. 2025;36(1):3.","journal-title":"Endocr Pathol"},{"issue":"2","key":"2697_CR91","doi-asserted-by":"publisher","first-page":"108","DOI":"10.1007\/s12022-020-09611-8","volume":"31","author":"WM Hackeng","year":"2020","unstructured":"Hackeng WM, Schelhaas W, Morsink FHM, Heidsma CM, van Eeden S, Valk GD, et al. Alternative Lengthening of Telomeres and Differential Expression of Endocrine Transcription Factors Distinguish Metastatic and Non-metastatic Insulinomas. Endocr Pathol. 2020;31(2):108\u201318.","journal-title":"Endocr Pathol"},{"key":"2697_CR92","doi-asserted-by":"crossref","unstructured":"Hackeng WM, Brosens LAA, Dreijerink KMA. Aggressive versus indolent insulinomas: new clinicopathological insights. Endocr Relat Cancer. 2023;30(5):e220321.","DOI":"10.1530\/ERC-22-0321"},{"issue":"4","key":"2697_CR93","doi-asserted-by":"publisher","first-page":"354","DOI":"10.1007\/s12022-024-09826-z","volume":"35","author":"P Mattiolo","year":"2024","unstructured":"Mattiolo P, Bevere M, Mafficini A, Verschuur AVD, Calicchia M, Hackeng WM, et al. Glucagon-Producing Pancreatic Neuroendocrine Tumors (Glucagonomas) are Enriched in Aggressive Neoplasms with ARX and PDX1 Co-expression, DAXX\/ATRX Mutations, and ALT (Alternative Lengthening of Telomeres). Endocr Pathol. 2024;35(4):354\u201361.","journal-title":"Endocr Pathol"},{"issue":"3","key":"2697_CR94","doi-asserted-by":"publisher","first-page":"100065","DOI":"10.1016\/j.modpat.2022.100065","volume":"36","author":"SE Umetsu","year":"2023","unstructured":"Umetsu SE, Kakar S, Basturk O, Kim GE, Chatterjee D, Wen KW, et al. Integrated Genomic and Clinicopathologic Approach Distinguishes Pancreatic Grade 3 Neuroendocrine Tumor From Neuroendocrine Carcinoma and Identifies a Subset With Molecular Overlap. Mod Pathol. 2023;36(3):100065.","journal-title":"Mod Pathol"},{"issue":"16","key":"2697_CR95","doi-asserted-by":"publisher","first-page":"4625","DOI":"10.1158\/1078-0432.CCR-16-3135","volume":"23","author":"S Hijioka","year":"2017","unstructured":"Hijioka S, Hosoda W, Matsuo K, Ueno M, Furukawa M, Yoshitomi H, et al. Rb Loss and KRAS Mutation Are Predictors of the Response to Platinum-Based Chemotherapy in Pancreatic Neuroendocrine Neoplasm with Grade 3: A Japanese Multicenter Pancreatic NEN-G3 Study. Clin Cancer Res. 2017;23(16):4625\u201332.","journal-title":"Clin Cancer Res"},{"key":"2697_CR96","doi-asserted-by":"publisher","first-page":"70","DOI":"10.1016\/j.humpath.2018.03.018","volume":"77","author":"B Konukiewitz","year":"2018","unstructured":"Konukiewitz B, Jesinghaus M, Steiger K, Schlitter AM, Kasajima A, Sipos B, et al. Pancreatic neuroendocrine carcinomas reveal a closer relationship to ductal adenocarcinomas than to neuroendocrine tumors G3. Hum Pathol. 2018;77:70\u20139.","journal-title":"Hum Pathol"},{"issue":"1","key":"2697_CR97","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1530\/ERC-21-0152","volume":"29","author":"A Venizelos","year":"2021","unstructured":"Venizelos A, Elvebakken H, Perren A, Nikolaienko O, Deng W, Lothe IMB, et al. The molecular characteristics of high-grade gastroenteropancreatic neuroendocrine neoplasms. Endocr Relat Cancer. 2021;29(1):1\u201314.","journal-title":"Endocr Relat Cancer"},{"issue":"4","key":"2697_CR98","doi-asserted-by":"publisher","first-page":"325","DOI":"10.1007\/s12022-024-09835-y","volume":"35","author":"NM Joseph","year":"2024","unstructured":"Joseph NM, Umetsu SE, Kim GE, Terry M, Perry A, Bergsland E, et al. Progression of Low-Grade Neuroendocrine Tumors (NET) to High-Grade Neoplasms Harboring the NEC-Like Co-alteration of RB1 and TP53. Endocr Pathol. 2024;35(4):325\u201337.","journal-title":"Endocr Pathol"},{"issue":"4","key":"2697_CR99","doi-asserted-by":"publisher","first-page":"313","DOI":"10.1007\/s12022-024-09827-y","volume":"35","author":"A Kasajima","year":"2024","unstructured":"Kasajima A, Pfarr N, Mayr EM, Ura A, Moser E, von Werder A, et al. Rapid Evolution of Metastases in Patients with Treated G3 Neuroendocrine Tumors Associated with NEC-Like Transformation and TP53 Mutation. Endocr Pathol. 2024;35(4):313\u201324.","journal-title":"Endocr Pathol"},{"issue":"5","key":"2697_CR100","doi-asserted-by":"publisher","first-page":"564","DOI":"10.1038\/bjc.2016.229","volume":"115","author":"N Vijayvergia","year":"2016","unstructured":"Vijayvergia N, Boland PM, Handorf E, Gustafson KS, Gong Y, Cooper HS, et al. Molecular profiling of neuroendocrine malignancies to identify prognostic and therapeutic markers: a Fox Chase Cancer Center Pilot Study. Br J Cancer. 2016;115(5):564\u201370.","journal-title":"Br J Cancer"},{"issue":"5","key":"2697_CR101","doi-asserted-by":"publisher","first-page":"324","DOI":"10.1159\/000481390","volume":"33","author":"G Kloppel","year":"2017","unstructured":"Kloppel G. Neuroendocrine Neoplasms: Dichotomy, Origin and Classifications. Visc Med. 2017;33(5):324\u201330.","journal-title":"Visc Med"},{"issue":"1","key":"2697_CR102","doi-asserted-by":"publisher","first-page":"192","DOI":"10.1007\/s12022-020-09660-z","volume":"32","author":"S Uccella","year":"2021","unstructured":"Uccella S, La Rosa S, Metovic J, Marchiori D, Scoazec JY, Volante M, et al. Genomics of High-Grade Neuroendocrine Neoplasms: Well-Differentiated Neuroendocrine Tumor with High-Grade Features (G3 NET) and Neuroendocrine Carcinomas (NEC) of Various Anatomic Sites. Endocr Pathol. 2021;32(1):192\u2013210.","journal-title":"Endocr Pathol"},{"issue":"1","key":"2697_CR103","doi-asserted-by":"publisher","first-page":"169","DOI":"10.1007\/s12022-021-09662-5","volume":"32","author":"SL Asa","year":"2021","unstructured":"Asa SL, La Rosa S, Basturk O, Adsay V, Minnetti M, Grossman AB. Molecular Pathology of Well-Differentiated Gastro-entero-pancreatic Neuroendocrine Tumors. Endocr Pathol. 2021;32(1):169\u201391.","journal-title":"Endocr Pathol"},{"issue":"1","key":"2697_CR104","doi-asserted-by":"publisher","first-page":"R37","DOI":"10.1530\/JME-12-0069","volume":"49","author":"G Capurso","year":"2012","unstructured":"Capurso G, Festa S, Valente R, Piciucchi M, Panzuto F, Jensen RT, et al. Molecular pathology and genetics of pancreatic endocrine tumours. J Mol Endocrinol. 2012;49(1):R37\u201350.","journal-title":"J Mol Endocrinol"},{"issue":"4","key":"2697_CR105","doi-asserted-by":"publisher","first-page":"507","DOI":"10.1530\/eje.0.1470507","volume":"147","author":"A Wild","year":"2002","unstructured":"Wild A, Langer P, Celik I, Chaloupka B, Bartsch DK. Chromosome 22q in pancreatic endocrine tumors: identification of a homozygous deletion and potential prognostic associations of allelic deletions. Eur J Endocrinol. 2002;147(4):507\u201313.","journal-title":"Eur J Endocrinol"},{"issue":"8","key":"2697_CR106","doi-asserted-by":"publisher","first-page":"110544","DOI":"10.1016\/j.isci.2024.110544","volume":"27","author":"A Tanaka","year":"2024","unstructured":"Tanaka A, Ogawa M, Zhou Y, Otani Y, Hendrickson RC, Miele MM, et al. Proteogenomic characterization of pancreatic neuroendocrine tumors uncovers hypoxia and immune signatures in clinically aggressive subtypes. iScience. 2024;27(8):110544.","journal-title":"iScience"},{"key":"2697_CR107","doi-asserted-by":"publisher","first-page":"18","DOI":"10.1038\/s41525-018-0058-3","volume":"3","author":"B Lawrence","year":"2018","unstructured":"Lawrence B, Blenkiron C, Parker K, Tsai P, Fitzgerald S, Shields P, et al. Recurrent loss of heterozygosity correlates with clinical outcome in pancreatic neuroendocrine cancer. NPJ Genom Med. 2018;3:18.","journal-title":"NPJ Genom Med"},{"issue":"6","key":"2697_CR108","doi-asserted-by":"publisher","first-page":"823","DOI":"10.1097\/PAS.0000000000001860","volume":"46","author":"M Parilla","year":"2022","unstructured":"Parilla M, Chapel D, Hechtman JF, Wanjari P, El Jabbour T, Sharma A, et al. Recurrent Loss of Heterozygosity in Pancreatic Neuroendocrine Tumors. Am J Surg Pathol. 2022;46(6):823\u201331.","journal-title":"Am J Surg Pathol"},{"issue":"3","key":"2697_CR109","doi-asserted-by":"publisher","first-page":"555","DOI":"10.1016\/j.path.2022.05.008","volume":"15","author":"V Tsvetkova","year":"2022","unstructured":"Tsvetkova V, Luchini C. Mixed Neuroendocrine-Non-Neuroendocrine Neoplasms of the Pancreas. Surg Pathol Clin. 2022;15(3):555\u201363.","journal-title":"Surg Pathol Clin"},{"issue":"7592","key":"2697_CR110","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1038\/nature16965","volume":"531","author":"P Bailey","year":"2016","unstructured":"Bailey P, Chang DK, Nones K, Johns AL, Patch AM, Gingras MC, et al. Genomic analyses identify molecular subtypes of pancreatic cancer. Nature. 2016;531(7592):47\u201352.","journal-title":"Nature"},{"issue":"3","key":"2697_CR111","doi-asserted-by":"publisher","first-page":"953","DOI":"10.1016\/S0002-9440(10)64917-6","volume":"160","author":"SC Abraham","year":"2002","unstructured":"Abraham SC, Wu TT, Hruban RH, Lee JH, Yeo CJ, Conlon K, et al. Genetic and immunohistochemical analysis of pancreatic acinar cell carcinoma: frequent allelic loss on chromosome 11p and alterations in the APC\/beta-catenin pathway. Am J Pathol. 2002;160(3):953\u201362.","journal-title":"Am J Pathol"},{"issue":"12","key":"2697_CR112","doi-asserted-by":"publisher","first-page":"1398","DOI":"10.1158\/2159-8290.CD-14-0617","volume":"4","author":"J Chmielecki","year":"2014","unstructured":"Chmielecki J, Hutchinson KE, Frampton GM, Chalmers ZR, Johnson A, Shi C, et al. Comprehensive genomic profiling of pancreatic acinar cell carcinomas identifies recurrent RAF fusions and frequent inactivation of DNA repair genes. Cancer Discov. 2014;4(12):1398\u2013405.","journal-title":"Cancer Discov"},{"key":"2697_CR113","doi-asserted-by":"publisher","first-page":"e2400450","DOI":"10.1200\/PO-24-00450","volume":"9","author":"C Eslinger","year":"2025","unstructured":"Eslinger C, Seddighzadeh B, Yee C, Elsabbagh Z, Pai R, Hartley C, et al. Clinical Outcomes and Molecular Profiling of Pancreatic Acinar Cell Carcinoma: A Retrospective Study. JCO Precis Oncol. 2025;9:e2400450.","journal-title":"JCO Precis Oncol"},{"issue":"7","key":"2697_CR114","doi-asserted-by":"publisher","first-page":"808","DOI":"10.5858\/arpa.2019-0472-RA","volume":"144","author":"ED Thompson","year":"2020","unstructured":"Thompson ED, Wood LD. Pancreatic Neoplasms With Acinar Differentiation: A Review of Pathologic and Molecular Features. Arch Pathol Lab Med. 2020;144(7):808\u201315.","journal-title":"Arch Pathol Lab Med"},{"issue":"1","key":"2697_CR115","doi-asserted-by":"publisher","first-page":"108","DOI":"10.1186\/s13000-021-01165-5","volume":"16","author":"J Chen","year":"2021","unstructured":"Chen J, Wang P, Lv K, Zhou W. Case report: composite pancreatic intraductal papillary mucinous neoplasm and neuroendocrine tumor: a new mixed neuroendocrine-non-neuroendocrine neoplasm? Diagn Pathol. 2021;16(1):108.","journal-title":"Diagn Pathol"},{"issue":"6","key":"2697_CR116","doi-asserted-by":"publisher","first-page":"1215","DOI":"10.1007\/s00428-020-02942-1","volume":"478","author":"M Schiavo Lena","year":"2021","unstructured":"Schiavo Lena M, Cangi MG, Pecciarini L, Francaviglia I, Grassini G, Maire R, et al. Evidence of a common cell origin in a case of pancreatic mixed intraductal papillary mucinous neoplasm-neuroendocrine tumor. Virchows Arch. 2021;478(6):1215\u20139.","journal-title":"Virchows Arch"},{"issue":"4","key":"2697_CR117","doi-asserted-by":"publisher","first-page":"310","DOI":"10.1159\/000369071","volume":"100","author":"M Scardoni","year":"2014","unstructured":"Scardoni M, Vittoria E, Volante M, Rusev B, Bersani S, Mafficini A, et al. Mixed adenoneuroendocrine carcinomas of the gastrointestinal tract: targeted next-generation sequencing suggests a monoclonal origin of the two components. Neuroendocrinology. 2014;100(4):310\u20136.","journal-title":"Neuroendocrinology"},{"issue":"4","key":"2697_CR118","doi-asserted-by":"publisher","first-page":"435","DOI":"10.1007\/s00428-018-2366-5","volume":"473","author":"S La Rosa","year":"2018","unstructured":"La Rosa S, Bernasconi B, Vanoli A, Sciarra A, Notohara K, Albarello L, et al. c-MYC amplification and c-myc protein expression in pancreatic acinar cell carcinomas. New insights into the molecular signature of these rare cancers. Virchows Arch. 2018;473(4):435\u201341.","journal-title":"Virchows Arch"},{"issue":"1","key":"2697_CR119","doi-asserted-by":"publisher","first-page":"4158","DOI":"10.1038\/s41467-018-06498-2","volume":"9","author":"CS Chan","year":"2018","unstructured":"Chan CS, Laddha SV, Lewis PW, Koletsky MS, Robzyk K, Da Silva E, et al. ATRX, DAXX or MEN1 mutant pancreatic neuroendocrine tumors are a distinct alpha-cell signature subgroup. Nat Commun. 2018;9(1):4158.","journal-title":"Nat Commun"},{"issue":"10","key":"2697_CR120","doi-asserted-by":"publisher","first-page":"1627","DOI":"10.1038\/s41591-019-0573-5","volume":"25","author":"P Cejas","year":"2019","unstructured":"Cejas P, Drier Y, Dreijerink KMA, Brosens LAA, Deshpande V, Epstein CB, et al. Publisher Correction: Enhancer signatures stratify and predict outcomes of non-functional pancreatic neuroendocrine tumors. Nat Med. 2019;25(10):1627.","journal-title":"Nat Med"},{"issue":"11","key":"2697_CR121","doi-asserted-by":"publisher","first-page":"100595","DOI":"10.1016\/j.modpat.2024.100595","volume":"37","author":"E Moser","year":"2024","unstructured":"Moser E, Ura A, Vogel L, Steiger K, Mogler C, Evert M, et al. ARX, PDX1, ISL1, and CDX2 Expression Distinguishes 5 Subgroups of Pancreatic Neuroendocrine Tumors With Correlations to Histology, Hormone Expression, and Outcome. Mod Pathol. 2024;37(11):100595.","journal-title":"Mod Pathol"},{"issue":"12","key":"2697_CR122","doi-asserted-by":"publisher","first-page":"1296","DOI":"10.1158\/2159-8290.CD-15-0068","volume":"5","author":"A Sadanandam","year":"2015","unstructured":"Sadanandam A, Wullschleger S, Lyssiotis CA, Grotzinger C, Barbi S, Bersani S, et al. A Cross-Species Analysis in Pancreatic Neuroendocrine Tumors Reveals Molecular Subtypes with Distinctive Clinical, Metastatic, Developmental, and Metabolic Characteristics. Cancer Discov. 2015;5(12):1296\u2013313.","journal-title":"Cancer Discov"},{"issue":"10","key":"2697_CR123","doi-asserted-by":"publisher","first-page":"1904","DOI":"10.1136\/gutjnl-2020-321016","volume":"70","author":"K Young","year":"2021","unstructured":"Young K, Lawlor RT, Ragulan C, Patil Y, Mafficini A, Bersani S, et al. Immune landscape, evolution, hypoxia-mediated viral mimicry pathways and therapeutic potential in molecular subtypes of pancreatic neuroendocrine tumours. Gut. 2021;70(10):1904\u201313.","journal-title":"Gut"},{"issue":"2","key":"2697_CR124","doi-asserted-by":"publisher","first-page":"109817","DOI":"10.1016\/j.celrep.2021.109817","volume":"37","author":"KC Yang","year":"2021","unstructured":"Yang KC, Kalloger SE, Aird JJ, Lee MKC, Rushton C, Mungall KL, et al. Proteotranscriptomic classification and characterization of pancreatic neuroendocrine neoplasms. Cell Rep. 2021;37(2):109817.","journal-title":"Cell Rep"},{"issue":"8","key":"2697_CR125","doi-asserted-by":"publisher","first-page":"563","DOI":"10.1530\/ERC-21-0051","volume":"28","author":"M Diedisheim","year":"2021","unstructured":"Diedisheim M, Dermine S, Jouinot A, Septier A, Gaujoux S, Dousset B, et al. Prognostic transcriptome classes of duodenopancreatic neuroendocrine tumors. Endocr Relat Cancer. 2021;28(8):563\u201371.","journal-title":"Endocr Relat Cancer"},{"issue":"4","key":"2697_CR126","doi-asserted-by":"publisher","first-page":"437","DOI":"10.1097\/PAS.0000000000000169","volume":"38","author":"O Basturk","year":"2014","unstructured":"Basturk O, Tang L, Hruban RH, Adsay V, Yang Z, Krasinskas AM, et al. Poorly differentiated neuroendocrine carcinomas of the pancreas: a clinicopathologic analysis of 44 cases. Am J Surg Pathol. 2014;38(4):437\u201347.","journal-title":"Am J Surg Pathol"},{"key":"2697_CR127","doi-asserted-by":"crossref","unstructured":"Wood-Trageser MA, Nichols CT, Hutchings DA, Bell D, Wald AI, Smith K et al. Recurrent BEND2 Fusion Genes Identified by Whole Transcriptome Sequencing of Non-Functional Pancreatic Neuroendocrine Tumors Correlate with Poor Patient Prognosis. Mod Pathol. 2025;38(10):100863.","DOI":"10.1016\/j.modpat.2025.100863"},{"issue":"14","key":"2697_CR128","doi-asserted-by":"publisher","first-page":"3760","DOI":"10.7150\/ijbs.61717","volume":"17","author":"Y Zhou","year":"2021","unstructured":"Zhou Y, Liu S, Liu C, Yang J, Lin Q, Zheng S, et al. Single-cell RNA sequencing reveals spatiotemporal heterogeneity and malignant progression in pancreatic neuroendocrine tumor. Int J Biol Sci. 2021;17(14):3760\u201375.","journal-title":"Int J Biol Sci"},{"issue":"9","key":"2697_CR129","doi-asserted-by":"publisher","first-page":"110836","DOI":"10.1016\/j.isci.2024.110836","volume":"27","author":"Z Ye","year":"2024","unstructured":"Ye Z, Zhou Y, Hu Y, Li Q, Xu Z, Lou X, et al. Single-cell sequencing reveals the heterogeneity of pancreatic neuroendocrine tumors under genomic instability and histological grading. iScience. 2024;27(9):110836.","journal-title":"iScience"},{"issue":"3","key":"2697_CR130","doi-asserted-by":"publisher","first-page":"507","DOI":"10.1007\/s00428-022-03484-4","volume":"482","author":"A Agaimy","year":"2023","unstructured":"Agaimy A, Kasajima A, Stoehr R, Haller F, Schubart C, Togel L, et al. Gene fusions are frequent in ACTH-secreting neuroendocrine neoplasms of the pancreas, but not in their non-pancreatic counterparts. Virchows Arch. 2023;482(3):507\u201316.","journal-title":"Virchows Arch"},{"key":"2697_CR131","doi-asserted-by":"publisher","first-page":"901435","DOI":"10.3389\/fonc.2022.901435","volume":"12","author":"JS Crabtree","year":"2022","unstructured":"Crabtree JS. Epigenetic Regulation in Gastroenteropancreatic Neuroendocrine Tumors. Front Oncol. 2022;12:901435.","journal-title":"Front Oncol"},{"issue":"1","key":"2697_CR132","doi-asserted-by":"publisher","first-page":"79","DOI":"10.1186\/s12943-020-01197-3","volume":"19","author":"Y Lu","year":"2020","unstructured":"Lu Y, Chan YT, Tan HY, Li S, Wang N, Feng Y. Epigenetic regulation in human cancer: the potential role of epi-drug in cancer therapy. Mol Cancer. 2020;19(1):79.","journal-title":"Mol Cancer"},{"issue":"8","key":"2697_CR133","doi-asserted-by":"publisher","first-page":"3104","DOI":"10.4103\/jfmpc.jfmpc_1287_24","volume":"14","author":"AA Almalki","year":"2025","unstructured":"Almalki AA. The role of epigenetics in cancer: From pathways to the clinic. J Family Med Prim Care. 2025;14(8):3104\u201314.","journal-title":"J Family Med Prim Care"},{"issue":"8","key":"2697_CR134","doi-asserted-by":"publisher","first-page":"732","DOI":"10.1016\/j.arcmed.2022.11.003","volume":"53","author":"F Recillas-Targa","year":"2022","unstructured":"Recillas-Targa F. Cancer Epigenetics: An Overview. Arch Med Res. 2022;53(8):732\u201340.","journal-title":"Arch Med Res"},{"issue":"6632","key":"2697_CR135","doi-asserted-by":"publisher","first-page":"eaaw3835","DOI":"10.1126\/science.aaw3835","volume":"379","author":"AP Feinberg","year":"2023","unstructured":"Feinberg AP, Levchenko A. Epigenetics as a mediator of plasticity in cancer. Science. 2023;379(6632):eaaw3835.","journal-title":"Science"},{"issue":"11","key":"2697_CR136","doi-asserted-by":"publisher","first-page":"1012","DOI":"10.1016\/j.tig.2021.05.002","volume":"37","author":"A Nishiyama","year":"2021","unstructured":"Nishiyama A, Nakanishi M. Navigating the DNA methylation landscape of cancer. Trends Genet. 2021;37(11):1012\u201327.","journal-title":"Trends Genet"},{"issue":"7","key":"2697_CR137","doi-asserted-by":"publisher","first-page":"484","DOI":"10.1038\/nrg3230","volume":"13","author":"PA Jones","year":"2012","unstructured":"Jones PA. Functions of DNA methylation: islands, start sites, gene bodies and beyond. Nat Rev Genet. 2012;13(7):484\u201392.","journal-title":"Nat Rev Genet"},{"issue":"21","key":"2697_CR138","doi-asserted-by":"publisher","first-page":"2042","DOI":"10.1056\/NEJMra023075","volume":"349","author":"JG Herman","year":"2003","unstructured":"Herman JG, Baylin SB. Gene silencing in cancer in association with promoter hypermethylation. N Engl J Med. 2003;349(21):2042\u201354.","journal-title":"N Engl J Med"},{"key":"2697_CR139","doi-asserted-by":"crossref","unstructured":"Simbolo M, Bilotta M, Mafficini A, Luchini C, Furlan D, Inzani F et al. Gene Expression Profiling of Pancreas Neuroendocrine Tumors with Different Ki67-Based Grades. Cancers (Basel). 2021;13(9):2054.","DOI":"10.3390\/cancers13092054"},{"issue":"12","key":"2697_CR140","doi-asserted-by":"publisher","first-page":"1632","DOI":"10.1038\/modpathol.3800490","volume":"18","author":"L Liu","year":"2005","unstructured":"Liu L, Broaddus RR, Yao JC, Xie S, White JA, Wu TT, et al. Epigenetic alterations in neuroendocrine tumors: methylation of RAS-association domain family 1, isoform A and p16 genes are associated with metastasis. Mod Pathol. 2005;18(12):1632\u201340.","journal-title":"Mod Pathol"},{"issue":"5","key":"2697_CR141","doi-asserted-by":"publisher","first-page":"953","DOI":"10.1093\/carcin\/bgt018","volume":"34","author":"JT Kim","year":"2013","unstructured":"Kim JT, Li J, Jang ER, Gulhati P, Rychahou PG, Napier DL, et al. Deregulation of Wnt\/beta-catenin signaling through genetic or epigenetic alterations in human neuroendocrine tumors. Carcinogenesis. 2013;34(5):953\u201361.","journal-title":"Carcinogenesis"},{"issue":"4","key":"2697_CR142","doi-asserted-by":"publisher","first-page":"409","DOI":"10.1002\/path.1784","volume":"206","author":"S Pizzi","year":"2005","unstructured":"Pizzi S, Azzoni C, Bottarelli L, Campanini N, D\u2019Adda T, Pasquali C, et al. RASSF1A promoter methylation and 3p21.3 loss of heterozygosity are features of foregut, but not midgut and hindgut, malignant endocrine tumours. J Pathol. 2005;206(4):409\u201316.","journal-title":"J Pathol"},{"issue":"92","key":"2697_CR143","first-page":"67","volume":"17","author":"M Guo","year":"2014","unstructured":"Guo M, Jia Y, Yu Z, House MG, Esteller M, Brock MV, et al. Epigenetic changes associated with neoplasms of the exocrine and endocrine pancreas. Discov Med. 2014;17(92):67\u201373.","journal-title":"Discov Med"},{"key":"2697_CR144","doi-asserted-by":"publisher","first-page":"351","DOI":"10.1186\/1471-2407-11-351","volume":"11","author":"G Malpeli","year":"2011","unstructured":"Malpeli G, Amato E, Dandrea M, Fumagalli C, Debattisti V, Boninsegna L, et al. Methylation-associated down-regulation of RASSF1A and up-regulation of RASSF1C in pancreatic endocrine tumors. BMC Cancer. 2011;11:351.","journal-title":"BMC Cancer"},{"issue":"3","key":"2697_CR145","doi-asserted-by":"publisher","first-page":"423","DOI":"10.1097\/01.sla.0000086659.49569.9e","volume":"238","author":"MG House","year":"2003","unstructured":"House MG, Herman JG, Guo MZ, Hooker CM, Schulick RD, Lillemoe KD, et al. Aberrant hypermethylation of tumor suppressor genes in pancreatic endocrine neoplasms. Ann Surg. 2003;238(3):423\u201331. discussion 31\u2009\u2013\u20092.","journal-title":"Ann Surg"},{"issue":"10","key":"2697_CR146","doi-asserted-by":"publisher","first-page":"2157","DOI":"10.1002\/ijc.22569","volume":"120","author":"CN Arnold","year":"2007","unstructured":"Arnold CN, Sosnowski A, Schmitt-Graff A, Arnold R, Blum HE. Analysis of molecular pathways in sporadic neuroendocrine tumors of the gastro-entero-pancreatic system. Int J Cancer. 2007;120(10):2157\u201364.","journal-title":"Int J Cancer"},{"issue":"4","key":"2697_CR147","doi-asserted-by":"publisher","first-page":"1219","DOI":"10.1677\/ERC-08-0297","volume":"16","author":"AM Schmitt","year":"2009","unstructured":"Schmitt AM, Schmid S, Rudolph T, Anlauf M, Prinz C, Kloppel G, et al. VHL inactivation is an important pathway for the development of malignant sporadic pancreatic endocrine tumors. Endocr Relat Cancer. 2009;16(4):1219\u201327.","journal-title":"Endocr Relat Cancer"},{"issue":"3","key":"2697_CR148","doi-asserted-by":"publisher","first-page":"1367","DOI":"10.1210\/jc.2002-021027","volume":"88","author":"A Wild","year":"2003","unstructured":"Wild A, Ramaswamy A, Langer P, Celik I, Fendrich V, Chaloupka B, et al. Frequent methylation-associated silencing of the tissue inhibitor of metalloproteinase-3 gene in pancreatic endocrine tumors. J Clin Endocrinol Metab. 2003;88(3):1367\u201373.","journal-title":"J Clin Endocrinol Metab"},{"key":"2697_CR149","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1186\/1756-8935-7-15","volume":"7","author":"S Schimmack","year":"2014","unstructured":"Schimmack S, Taylor A, Lawrence B, Alaimo D, Schmitz-Winnenthal H, Buchler MW, et al. A mechanistic role for the chromatin modulator, NAP1L1, in pancreatic neuroendocrine neoplasm proliferation and metastases. Epigenetics Chromatin. 2014;7:15.","journal-title":"Epigenetics Chromatin"},{"issue":"8","key":"2697_CR150","doi-asserted-by":"publisher","first-page":"2060","DOI":"10.1053\/j.gastro.2018.02.026","volume":"154","author":"S Roy","year":"2018","unstructured":"Roy S, LaFramboise WA, Liu TC, Cao D, Luvison A, Miller C, et al. Loss of Chromatin-Remodeling Proteins and\/or CDKN2A Associates With Metastasis of Pancreatic Neuroendocrine Tumors and Reduced Patient Survival Times. Gastroenterology. 2018;154(8):2060\u20133. e8.","journal-title":"Gastroenterology"},{"issue":"3","key":"2697_CR151","doi-asserted-by":"publisher","first-page":"764","DOI":"10.1002\/1878-0261.13107","volume":"16","author":"S Pedraza-Arevalo","year":"2022","unstructured":"Pedraza-Arevalo S, Ibanez-Costa A, Blazquez-Encinas R, Branco MR, Vazquez-Borrego MC, Herrera-Martinez AD, et al. Epigenetic and post-transcriptional regulation of somatostatin receptor subtype 5 (SST(5)) in pituitary and pancreatic neuroendocrine tumors. Mol Oncol. 2022;16(3):764\u201379.","journal-title":"Mol Oncol"},{"issue":"10","key":"2697_CR152","doi-asserted-by":"publisher","first-page":"3285","DOI":"10.1210\/clinem\/dgaa477","volume":"105","author":"A Tirosh","year":"2020","unstructured":"Tirosh A, Killian JK, Petersen D, Zhu YJ, Walker RL, Blau JE, et al. Distinct DNA Methylation Signatures in Neuroendocrine Tumors Specific for Primary Site and Inherited Predisposition. J Clin Endocrinol Metab. 2020;105(10):3285\u201394.","journal-title":"J Clin Endocrinol Metab"},{"issue":"6","key":"2697_CR153","doi-asserted-by":"publisher","first-page":"1245","DOI":"10.1016\/j.cgh.2024.02.007","volume":"22","author":"AVD Verschuur","year":"2024","unstructured":"Verschuur AVD, Hackeng WM, Westerbeke F, Benhamida JK, Basturk O, Selenica P, et al. DNA Methylation Profiling Enables Accurate Classification of Nonductal Primary Pancreatic Neoplasms. Clin Gastroenterol Hepatol. 2024;22(6):1245\u2013e5410.","journal-title":"Clin Gastroenterol Hepatol"},{"key":"2697_CR154","doi-asserted-by":"crossref","unstructured":"Boons G, Vandamme T, Ibrahim J, Roeyen G, Driessen A, Peeters D et al. PDX1 DNA Methylation Distinguishes Two Subtypes of Pancreatic Neuroendocrine Neoplasms with a Different Prognosis. Cancers (Basel). 2020;12(6):1461.","DOI":"10.3390\/cancers12061461"},{"issue":"1","key":"2697_CR155","doi-asserted-by":"publisher","first-page":"740","DOI":"10.1038\/s42003-020-01479-y","volume":"3","author":"A Di Domenico","year":"2020","unstructured":"Di Domenico A, Pipinikas CP, Maire RS, Brautigam K, Simillion C, Dettmer MS, et al. Epigenetic landscape of pancreatic neuroendocrine tumours reveals distinct cells of origin and means of tumour progression. Commun Biol. 2020;3(1):740.","journal-title":"Commun Biol"},{"issue":"1","key":"2697_CR156","doi-asserted-by":"publisher","first-page":"155","DOI":"10.1038\/s42003-020-01469-0","volume":"4","author":"V Lakis","year":"2021","unstructured":"Lakis V, Lawlor RT, Newell F, Patch AM, Mafficini A, Sadanandam A, et al. DNA methylation patterns identify subgroups of pancreatic neuroendocrine tumors with clinical association. Commun Biol. 2021;4(1):155.","journal-title":"Commun Biol"},{"issue":"1","key":"2697_CR157","doi-asserted-by":"publisher","first-page":"24","DOI":"10.1186\/s13073-022-01018-w","volume":"14","author":"T Simon","year":"2022","unstructured":"Simon T, Riemer P, Jarosch A, Detjen K, Di Domenico A, Bormann F, et al. DNA methylation reveals distinct cells of origin for pancreatic neuroendocrine carcinomas and pancreatic neuroendocrine tumors. Genome Med. 2022;14(1):24.","journal-title":"Genome Med"},{"key":"2697_CR158","doi-asserted-by":"crossref","unstructured":"Galasso L, Vitale F, Giansanti G, Esposto G, Borriello R, Mignini I et al. Decoding Pancreatic Neuroendocrine Tumors: Molecular Profiles, Biomarkers, and Pathways to Personalized Therapy. Int J Mol Sci. 2025;26(16):7814.","DOI":"10.3390\/ijms26167814"},{"issue":"3","key":"2697_CR159","doi-asserted-by":"publisher","first-page":"273","DOI":"10.1016\/j.stem.2015.07.022","volume":"17","author":"Q He","year":"2015","unstructured":"He Q, Kim H, Huang R, Lu W, Tang M, Shi F, et al. The Daxx\/Atrx Complex Protects Tandem Repetitive Elements during DNA Hypomethylation by Promoting H3K9 Trimethylation. Cell Stem Cell. 2015;17(3):273\u201386.","journal-title":"Cell Stem Cell"},{"issue":"4","key":"2697_CR160","doi-asserted-by":"publisher","first-page":"587","DOI":"10.1016\/S1097-2765(04)00081-4","volume":"13","author":"CM Hughes","year":"2004","unstructured":"Hughes CM, Rozenblatt-Rosen O, Milne TA, Copeland TD, Levine SS, Lee JC, et al. Menin associates with a trithorax family histone methyltransferase complex and with the hoxc8 locus. Mol Cell. 2004;13(4):587\u201397.","journal-title":"Mol Cell"},{"issue":"31","key":"2697_CR161","doi-asserted-by":"publisher","first-page":"50719","DOI":"10.18632\/oncotarget.9368","volume":"7","author":"J Li","year":"2016","unstructured":"Li J, Duns G, Westers H, Sijmons R, van den Berg A, Kok K. SETD2: an epigenetic modifier with tumor suppressor functionality. Oncotarget. 2016;7(31):50719\u201334.","journal-title":"Oncotarget"},{"issue":"3","key":"2697_CR162","doi-asserted-by":"publisher","first-page":"L13","DOI":"10.1530\/ERC-15-0108","volume":"22","author":"CP Pipinikas","year":"2015","unstructured":"Pipinikas CP, Dibra H, Karpathakis A, Feber A, Novelli M, Oukrif D, et al. Epigenetic dysregulation and poorer prognosis in DAXX-deficient pancreatic neuroendocrine tumours. Endocr Relat Cancer. 2015;22(3):L13\u20138.","journal-title":"Endocr Relat Cancer"},{"issue":"4","key":"2697_CR163","doi-asserted-by":"publisher","first-page":"689","DOI":"10.1158\/1541-7786.MCR-14-0457","volume":"13","author":"W Lin","year":"2015","unstructured":"Lin W, Watanabe H, Peng S, Francis JM, Kaplan N, Pedamallu CS, et al. Dynamic epigenetic regulation by menin during pancreatic islet tumor formation. Mol Cancer Res. 2015;13(4):689\u201398.","journal-title":"Mol Cancer Res"},{"issue":"7","key":"2697_CR164","doi-asserted-by":"publisher","first-page":"e1002772","DOI":"10.1371\/journal.pgen.1002772","volume":"8","author":"CA Lovejoy","year":"2012","unstructured":"Lovejoy CA, Li W, Reisenweber S, Thongthip S, Bruno J, de Lange T, et al. Loss of ATRX, genome instability, and an altered DNA damage response are hallmarks of the alternative lengthening of telomeres pathway. PLoS Genet. 2012;8(7):e1002772.","journal-title":"PLoS Genet"},{"key":"2697_CR165","doi-asserted-by":"publisher","first-page":"101131","DOI":"10.1016\/j.currproblcancer.2024.101131","volume":"52","author":"HS McMurry","year":"2024","unstructured":"McMurry HS, Rivero JD, Chen EY, Kardosh A, Lopez CD, Pegna GJ. Gastroenteropancreatic neuroendocrine tumors: Epigenetic landscape and clinical implications. Curr Probl Cancer. 2024;52:101131.","journal-title":"Curr Probl Cancer"},{"key":"2697_CR166","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1016\/j.humpath.2017.02.009","volume":"65","author":"E Klieser","year":"2017","unstructured":"Klieser E, Urbas R, Stattner S, Primavesi F, Jager T, Dinnewitzer A, et al. Comprehensive immunohistochemical analysis of histone deacetylases in pancreatic neuroendocrine tumors: HDAC5 as a predictor of poor clinical outcome. Hum Pathol. 2017;65:41\u201352.","journal-title":"Hum Pathol"},{"issue":"1","key":"2697_CR167","doi-asserted-by":"publisher","first-page":"5210","DOI":"10.1038\/s41467-020-18839-1","volume":"11","author":"E Karakose","year":"2020","unstructured":"Karakose E, Wang H, Inabnet W, Thakker RV, Libutti S, Fernandez-Ranvier G, et al. Aberrant methylation underlies insulin gene expression in human insulinoma. Nat Commun. 2020;11(1):5210.","journal-title":"Nat Commun"},{"issue":"11","key":"2697_CR168","doi-asserted-by":"publisher","first-page":"4146","DOI":"10.1210\/jcem.85.11.6970","volume":"85","author":"J Serrano","year":"2000","unstructured":"Serrano J, Goebel SU, Peghini PL, Lubensky IA, Gibril F, Jensen RT. Alterations in the p16INK4a\/CDKN2A tumor suppressor gene in gastrinomas. J Clin Endocrinol Metab. 2000;85(11):4146\u201356.","journal-title":"J Clin Endocrinol Metab"},{"issue":"6","key":"2697_CR169","doi-asserted-by":"publisher","first-page":"1185","DOI":"10.1016\/j.surg.2013.06.018","volume":"154","author":"JM Kinross","year":"2013","unstructured":"Kinross JM, Drymousis P, Jimenez B, Frilling A. Metabonomic profiling: a novel approach in neuroendocrine neoplasias. Surgery. 2013;154(6):1185\u201392. discussion 92\u2009\u2013\u20093.","journal-title":"Surgery"},{"issue":"1","key":"2697_CR170","doi-asserted-by":"publisher","first-page":"50","DOI":"10.1007\/s00018-023-05084-0","volume":"81","author":"C Hu","year":"2024","unstructured":"Hu C, Ye M, Bai J, Liu P, Lu F, Chen J, et al. FOXA2-initiated transcriptional activation of INHBA induced by methylmalonic acid promotes pancreatic neuroendocrine neoplasm progression. Cell Mol Life Sci. 2024;81(1):50.","journal-title":"Cell Mol Life Sci"},{"issue":"4","key":"2697_CR171","doi-asserted-by":"publisher","first-page":"466","DOI":"10.1093\/ejendo\/lvaf055","volume":"192","author":"A Jannin","year":"2025","unstructured":"Jannin A, Dabo-Niang S, Do Cao C, Descat A, Espiard S, Cardot-Bauters C, et al. Identification of metabolite biomarkers for pancreatic neuroendocrine tumours using a metabolomic approach. Eur J Endocrinol. 2025;192(4):466\u201380.","journal-title":"Eur J Endocrinol"},{"key":"2697_CR172","doi-asserted-by":"crossref","unstructured":"Jimenez B, Abellona UM, Drymousis P, Kyriakides M, Clift AK, Liu DSK et al. Neuroendocrine Neoplasms: Identification of Novel Metabolic Circuits of Potential Diagnostic Utility. Cancers (Basel). 2021;13(3):374.","DOI":"10.3390\/cancers13030374"},{"key":"2697_CR173","doi-asserted-by":"publisher","first-page":"1248575","DOI":"10.3389\/fendo.2023.1248575","volume":"14","author":"A Jannin","year":"2023","unstructured":"Jannin A, Dessein AF, Do Cao C, Vantyghem MC, Chevalier B, Van Seuningen I, et al. Metabolism of pancreatic neuroendocrine tumors: what can omics tell us? Front Endocrinol (Lausanne). 2023;14:1248575.","journal-title":"Front Endocrinol (Lausanne)"},{"issue":"6788","key":"2697_CR174","doi-asserted-by":"publisher","first-page":"837","DOI":"10.1038\/35015709","volume":"405","author":"A Pandey","year":"2000","unstructured":"Pandey A, Mann M. Proteomics to study genes and genomes. Nature. 2000;405(6788):837\u201346.","journal-title":"Nature"},{"key":"2697_CR175","doi-asserted-by":"publisher","first-page":"120302","DOI":"10.1016\/j.cca.2025.120302","volume":"574","author":"E Gheybi","year":"2025","unstructured":"Gheybi E, Hosseinzadeh P, Tayebi-Khorrami V, Rostami M, Soukhtanloo M. Proteomics in decoding cancer: A review. Clin Chim Acta. 2025;574:120302.","journal-title":"Clin Chim Acta"},{"issue":"7502","key":"2697_CR176","doi-asserted-by":"publisher","first-page":"582","DOI":"10.1038\/nature13319","volume":"509","author":"M Wilhelm","year":"2014","unstructured":"Wilhelm M, Schlegl J, Hahne H, Gholami AM, Lieberenz M, Savitski MM, et al. Mass-spectrometry-based draft of the human proteome. Nature. 2014;509(7502):582\u20137.","journal-title":"Nature"},{"key":"2697_CR177","doi-asserted-by":"publisher","first-page":"100155","DOI":"10.1016\/j.mcpro.2021.100155","volume":"20","author":"AH Ren","year":"2021","unstructured":"Ren AH, Diamandis EP, Kulasingam V. Uncovering the Depths of the Human Proteome: Antibody-based Technologies for Ultrasensitive Multiplexed Protein Detection and Quantification. Mol Cell Proteom. 2021;20:100155.","journal-title":"Mol Cell Proteom"},{"issue":"8046","key":"2697_CR178","doi-asserted-by":"publisher","first-page":"726","DOI":"10.1038\/s41586-024-08225-y","volume":"637","author":"P Huang","year":"2025","unstructured":"Huang P, Gao W, Fu C, Wang M, Li Y, Chu B, et al. Clinical functional proteomics of intercellular signalling in pancreatic cancer. Nature. 2025;637(8046):726\u201335.","journal-title":"Nature"},{"issue":"36","key":"2697_CR179","doi-asserted-by":"publisher","first-page":"24291","DOI":"10.18632\/oncotarget.25110","volume":"9","author":"M Shimura","year":"2018","unstructured":"Shimura M, Mizuma M, Takadate T, Katoh Y, Suzuki T, Iseki M, et al. A novel liver metastasis-correlated protein of pancreatic neuroendocrine neoplasm (PanNEN) discovered by proteomic analysis. Oncotarget. 2018;9(36):24291\u2013303.","journal-title":"Oncotarget"},{"issue":"4","key":"2697_CR180","doi-asserted-by":"publisher","first-page":"776","DOI":"10.1016\/j.ccell.2025.03.016","volume":"43","author":"S Ji","year":"2025","unstructured":"Ji S, Cao L, Gao J, Du Y, Ye Z, Lou X, et al. Proteogenomic characterization of non-functional pancreatic neuroendocrine tumors unravels clinically relevant subgroups. Cancer Cell. 2025;43(4):776\u201396. e14.","journal-title":"Cancer Cell"},{"issue":"1","key":"2697_CR181","doi-asserted-by":"publisher","first-page":"69","DOI":"10.1038\/modpathol.2014.82","volume":"28","author":"I Alkatout","year":"2015","unstructured":"Alkatout I, Friemel J, Sitek B, Anlauf M, Eisenach PA, Stuhler K, et al. Novel prognostic markers revealed by a proteomic approach separating benign from malignant insulinomas. Mod Pathol. 2015;28(1):69\u201379.","journal-title":"Mod Pathol"},{"issue":"16","key":"2697_CR182","doi-asserted-by":"publisher","first-page":"1414","DOI":"10.1002\/rcm.8183","volume":"32","author":"RG Kay","year":"2018","unstructured":"Kay RG, Challis BG, Casey RT, Roberts GP, Meek CL, Reimann F, et al. Peptidomic analysis of endogenous plasma peptides from patients with pancreatic neuroendocrine tumours. Rapid Commun Mass Spectrom. 2018;32(16):1414\u201324.","journal-title":"Rapid Commun Mass Spectrom"},{"issue":"4","key":"2697_CR183","doi-asserted-by":"publisher","first-page":"132","DOI":"10.1109\/MSP.2019.2900993","volume":"36","author":"P Afshar","year":"2019","unstructured":"Afshar P, Mohammadi A, Plataniotis KN, Oikonomou A, Benali H. From Handcrafted to Deep-Learning-Based Cancer Radiomics: Challenges and Opportunities. IEEE Signal Process Mag. 2019;36(4):132\u201360.","journal-title":"IEEE Signal Process Mag"},{"issue":"2","key":"2697_CR184","doi-asserted-by":"publisher","first-page":"563","DOI":"10.1148\/radiol.2015151169","volume":"278","author":"RJ Gillies","year":"2016","unstructured":"Gillies RJ, Kinahan PE, Hricak H. Radiomics: Images Are More than Pictures, They Are Data. Radiology. 2016;278(2):563\u201377.","journal-title":"Radiology"},{"issue":"10","key":"2697_CR185","doi-asserted-by":"publisher","first-page":"7278","DOI":"10.1007\/s00330-022-08996-w","volume":"32","author":"FCR Staal","year":"2022","unstructured":"Staal FCR, Aalbersberg EA, van der Velden D, Wilthagen EA, Tesselaar MET, Beets-Tan RGH, et al. GEP-NET radiomics: a systematic review and radiomics quality score assessment. Eur Radiol. 2022;32(10):7278\u201394.","journal-title":"Eur Radiol"},{"issue":"2","key":"2697_CR186","doi-asserted-by":"publisher","first-page":"275","DOI":"10.3748\/wjg.v23.i2.275","volume":"23","author":"R De Robertis","year":"2017","unstructured":"De Robertis R, Cingarlini S, Tinazzi Martini P, Ortolani S, Butturini G, Landoni L, et al. Pancreatic neuroendocrine neoplasms: Magnetic resonance imaging features according to grade and stage. World J Gastroenterol. 2017;23(2):275\u201385.","journal-title":"World J Gastroenterol"},{"issue":"6","key":"2697_CR187","doi-asserted-by":"publisher","first-page":"943","DOI":"10.1007\/s13244-018-0658-6","volume":"9","author":"V Ciaravino","year":"2018","unstructured":"Ciaravino V, De Robertis R, Tinazzi Martini P, Cardobi N, Cingarlini S, Amodio A, et al. Imaging presentation of pancreatic neuroendocrine neoplasms. Insights Imaging. 2018;9(6):943\u201353.","journal-title":"Insights Imaging"},{"key":"2697_CR188","doi-asserted-by":"publisher","first-page":"100651","DOI":"10.1016\/j.ejro.2025.100651","volume":"14","author":"R De Robertis","year":"2025","unstructured":"De Robertis R, Mascarin B, Bardhi E, Spoto F, Cardobi N, D\u2019Onofrio M. Radiomics in differential diagnosis of pancreatic tumors. Eur J Radiol Open. 2025;14:100651.","journal-title":"Eur J Radiol Open"},{"issue":"10","key":"2697_CR189","doi-asserted-by":"publisher","first-page":"4924","DOI":"10.1002\/cam4.1746","volume":"7","author":"J Li","year":"2018","unstructured":"Li J, Lu J, Liang P, Li A, Hu Y, Shen Y, et al. Differentiation of atypical pancreatic neuroendocrine tumors from pancreatic ductal adenocarcinomas: Using whole-tumor CT texture analysis as quantitative biomarkers. Cancer Med. 2018;7(10):4924\u201331.","journal-title":"Cancer Med"},{"issue":"9","key":"2697_CR190","doi-asserted-by":"publisher","first-page":"4523","DOI":"10.1007\/s00261-021-03084-x","volume":"46","author":"CP Reinert","year":"2021","unstructured":"Reinert CP, Baumgartner K, Hepp T, Bitzer M, Horger M. Correction to: Complementary role of computed tomography texture analysis for differentiation of pancreatic ductal adenocarcinoma from pancreatic neuroendocrine tumors in the portal\u2013venous enhancement phase. Abdom Radiol (NY). 2021;46(9):4523.","journal-title":"Abdom Radiol (NY)"},{"issue":"5","key":"2697_CR191","doi-asserted-by":"publisher","first-page":"595","DOI":"10.1177\/0284185119875023","volume":"61","author":"Z Wang","year":"2020","unstructured":"Wang Z, Chen X, Wang J, Cui W, Ren S, Wang Z. Differentiating hypovascular pancreatic neuroendocrine tumors from pancreatic ductal adenocarcinoma based on CT texture analysis. Acta Radiol. 2020;61(5):595\u2013604.","journal-title":"Acta Radiol"},{"key":"2697_CR192","doi-asserted-by":"publisher","first-page":"102","DOI":"10.1016\/j.ejrad.2019.05.024","volume":"117","author":"M He","year":"2019","unstructured":"He M, Liu Z, Lin Y, Wan J, Li J, Xu K, et al. Differentiation of atypical non-functional pancreatic neuroendocrine tumor and pancreatic ductal adenocarcinoma using CT based radiomics. Eur J Radiol. 2019;117:102\u201311.","journal-title":"Eur J Radiol"},{"issue":"4","key":"2697_CR193","doi-asserted-by":"publisher","first-page":"e2574","DOI":"10.1097\/MD.0000000000002574","volume":"95","author":"T Shindo","year":"2016","unstructured":"Shindo T, Fukukura Y, Umanodan T, Takumi K, Hakamada H, Nakajo M, et al. Histogram Analysis of Apparent Diffusion Coefficient in Differentiating Pancreatic Adenocarcinoma and Neuroendocrine Tumor. Med (Baltim). 2016;95(4):e2574.","journal-title":"Med (Baltim)"},{"issue":"1","key":"2697_CR194","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/S1001-9294(12)60014-5","volume":"34","author":"YW Wang","year":"2019","unstructured":"Wang YW, Zhang XH, Wang BT, Wang Y, Liu MQ, Wang HY, et al. Value of Texture Analysis of Intravoxel Incoherent Motion Parameters in Differential Diagnosis of Pancreatic Neuroendocrine Tumor and Pancreatic Adenocarcinoma. Chin Med Sci J. 2019;34(1):1\u20139.","journal-title":"Chin Med Sci J"},{"issue":"5","key":"2697_CR195","doi-asserted-by":"publisher","first-page":"1073","DOI":"10.2214\/AJR.18.20715","volume":"213","author":"R De Robertis","year":"2019","unstructured":"De Robertis R, Marchegiani G, Catania M, Ambrosetti MC, Capelli P, Salvia R, et al. Solid Pseudopapillary Neoplasms of the Pancreas: Clinicopathologic and Radiologic Features According to Size. AJR Am J Roentgenol. 2019;213(5):1073\u201380.","journal-title":"AJR Am J Roentgenol"},{"key":"2697_CR196","doi-asserted-by":"publisher","first-page":"1624","DOI":"10.3389\/fonc.2020.01624","volume":"10","author":"YJ Shi","year":"2020","unstructured":"Shi YJ, Zhu HT, Liu YL, Wei YY, Qin XB, Zhang XY, et al. Radiomics Analysis Based on Diffusion Kurtosis Imaging and T2 Weighted Imaging for Differentiation of Pancreatic Neuroendocrine Tumors From Solid Pseudopapillary Tumors. Front Oncol. 2020;10:1624.","journal-title":"Front Oncol"},{"issue":"6","key":"2697_CR197","doi-asserted-by":"publisher","first-page":"815","DOI":"10.1016\/j.acra.2019.07.012","volume":"27","author":"X Li","year":"2020","unstructured":"Li X, Zhu H, Qian X, Chen N, Lin X. MRI Texture Analysis for Differentiating Nonfunctional Pancreatic Neuroendocrine Neoplasms From Solid Pseudopapillary Neoplasms of the Pancreas. Acad Radiol. 2020;27(6):815\u201323.","journal-title":"Acad Radiol"},{"key":"2697_CR198","doi-asserted-by":"publisher","unstructured":"ChakrabortyJ, Pulvirenti A, Yamashita R, Midya A, G\u00f6nen M, Klimstra D, et al. Quantitative CT analysis for the preoperative prediction of pathologic grade in pancreatic neuroendocrine tumors. Proc. SPIE 10575, Medical Imaging 2018: Computer-Aided Diagnosis, 105751N (27 Feb 2018); https:\/\/doi.org\/10.1117\/12.2293577.","DOI":"10.1117\/12.2293577"},{"issue":"2","key":"2697_CR199","doi-asserted-by":"publisher","first-page":"576","DOI":"10.1007\/s00261-018-1763-1","volume":"44","author":"C Guo","year":"2019","unstructured":"Guo C, Zhuge X, Wang Z, Wang Q, Sun K, Feng Z, et al. Textural analysis on contrast-enhanced CT in pancreatic neuroendocrine neoplasms: association with WHO grade. Abdom Radiol (NY). 2019;44(2):576\u201385.","journal-title":"Abdom Radiol (NY)"},{"issue":"5","key":"2697_CR200","doi-asserted-by":"publisher","first-page":"338","DOI":"10.1159\/000503291","volume":"110","author":"Y Luo","year":"2020","unstructured":"Luo Y, Chen X, Chen J, Song C, Shen J, Xiao H, et al. Preoperative Prediction of Pancreatic Neuroendocrine Neoplasms Grading Based on Enhanced Computed Tomography Imaging: Validation of Deep Learning with a Convolutional Neural Network. Neuroendocrinology. 2020;110(5):338\u201350.","journal-title":"Neuroendocrinology"},{"key":"2697_CR201","first-page":"679","volume":"5","author":"A Pulvirenti","year":"2021","unstructured":"Pulvirenti A, Yamashita R, Chakraborty J, Horvat N, Seier K, McIntyre CA, et al. Quantitative Computed Tomography Image Analysis to Predict Pancreatic Neuroendocrine Tumor Grade. JCO Clin Cancer Inf. 2021;5:679\u201394.","journal-title":"JCO Clin Cancer Inf"},{"issue":"21","key":"2697_CR202","doi-asserted-by":"publisher","first-page":"215009","DOI":"10.1088\/1361-6560\/ab489f","volume":"64","author":"L Xu","year":"2019","unstructured":"Xu L, Yang P, Yen EA, Wan Y, Jiang Y, Cao Z, et al. A multi-organ cancer study of the classification performance using 2D and 3D image features in radiomics analysis. Phys Med Biol. 2019;64(21):215009.","journal-title":"Phys Med Biol"},{"issue":"12","key":"2697_CR203","doi-asserted-by":"publisher","first-page":"e272","DOI":"10.1016\/j.acra.2020.01.002","volume":"27","author":"Z Zhao","year":"2020","unstructured":"Zhao Z, Bian Y, Jiang H, Fang X, Li J, Cao K, et al. CT-Radiomic Approach to Predict G1\/2 Nonfunctional Pancreatic Neuroendocrine Tumor. Acad Radiol. 2020;27(12):e272\u201381.","journal-title":"Acad Radiol"},{"issue":"4","key":"2697_CR204","doi-asserted-by":"publisher","first-page":"852","DOI":"10.2214\/AJR.19.22123","volume":"215","author":"Y Bian","year":"2020","unstructured":"Bian Y, Jiang H, Ma C, Wang L, Zheng J, Jin G, et al. CT-Based Radiomics Score for Distinguishing Between Grade 1 and Grade 2 Nonfunctioning Pancreatic Neuroendocrine Tumors. AJR Am J Roentgenol. 2020;215(4):852\u201363.","journal-title":"AJR Am J Roentgenol"},{"issue":"12","key":"2697_CR205","doi-asserted-by":"publisher","first-page":"6880","DOI":"10.1007\/s00330-019-06176-x","volume":"29","author":"D Gu","year":"2019","unstructured":"Gu D, Hu Y, Ding H, Wei J, Chen K, Liu H, et al. CT radiomics may predict the grade of pancreatic neuroendocrine tumors: a multicenter study. Eur Radiol. 2019;29(12):6880\u201390.","journal-title":"Eur Radiol"},{"issue":"2","key":"2697_CR206","doi-asserted-by":"publisher","first-page":"584","DOI":"10.1158\/1078-0432.CCR-18-1305","volume":"25","author":"W Liang","year":"2019","unstructured":"Liang W, Yang P, Huang R, Xu L, Wang J, Liu W, et al. A Combined Nomogram Model to Preoperatively Predict Histologic Grade in Pancreatic Neuroendocrine Tumors. Clin Cancer Res. 2019;25(2):584\u201394.","journal-title":"Clin Cancer Res"},{"issue":"4","key":"2697_CR207","doi-asserted-by":"publisher","first-page":"e49","DOI":"10.1016\/j.acra.2021.05.017","volume":"29","author":"C Liu","year":"2022","unstructured":"Liu C, Bian Y, Meng Y, Liu F, Cao K, Zhang H, et al. Preoperative Prediction of G1 and G2\/3 Grades in Patients With Nonfunctional Pancreatic Neuroendocrine Tumors Using Multimodality Imaging. Acad Radiol. 2022;29(4):e49\u201360.","journal-title":"Acad Radiol"},{"key":"2697_CR208","doi-asserted-by":"crossref","unstructured":"Beleu A, Rizzo G, De Robertis R, Drudi A, Aluffi G, Longo C et al. Liver Tumor Burden in Pancreatic Neuroendocrine Tumors: CT Features and Texture Analysis in the Prediction of Tumor Grade and (18)F-FDG Uptake. Cancers (Basel). 2020;12(6):1486.","DOI":"10.3390\/cancers12061486"},{"issue":"2","key":"2697_CR209","doi-asserted-by":"publisher","first-page":"341","DOI":"10.2214\/AJR.17.18417","volume":"210","author":"R Canellas","year":"2018","unstructured":"Canellas R, Burk KS, Parakh A, Sahani DV. Prediction of Pancreatic Neuroendocrine Tumor Grade Based on CT Features and Texture Analysis. AJR Am J Roentgenol. 2018;210(2):341\u20136.","journal-title":"AJR Am J Roentgenol"},{"issue":"2","key":"2697_CR210","doi-asserted-by":"publisher","first-page":"667","DOI":"10.1007\/s00261-020-02706-0","volume":"46","author":"Y Bian","year":"2021","unstructured":"Bian Y, Li J, Cao K, Fang X, Jiang H, Ma C, et al. Magnetic resonance imaging radiomic analysis can preoperatively predict G1 and G2\/3 grades in patients with NF-pNETs. Abdom Radiol (NY). 2021;46(2):667\u201380.","journal-title":"Abdom Radiol (NY)"},{"issue":"4","key":"2697_CR211","doi-asserted-by":"publisher","first-page":"1124","DOI":"10.1002\/jmri.27176","volume":"52","author":"Y Bian","year":"2020","unstructured":"Bian Y, Zhao Z, Jiang H, Fang X, Li J, Cao K, et al. Noncontrast Radiomics Approach for Predicting Grades of Nonfunctional Pancreatic Neuroendocrine Tumors. J Magn Reson Imaging. 2020;52(4):1124\u201336.","journal-title":"J Magn Reson Imaging"},{"issue":"6","key":"2697_CR212","doi-asserted-by":"publisher","first-page":"2582","DOI":"10.1007\/s00330-017-5236-7","volume":"28","author":"R De Robertis","year":"2018","unstructured":"De Robertis R, Maris B, Cardobi N, Tinazzi Martini P, Gobbo S, Capelli P, et al. Can histogram analysis of MR images predict aggressiveness in pancreatic neuroendocrine tumors? Eur Radiol. 2018;28(6):2582\u201391.","journal-title":"Eur Radiol"},{"issue":"8","key":"2697_CR213","doi-asserted-by":"publisher","first-page":"3122","DOI":"10.1007\/s00261-015-0524-7","volume":"40","author":"JA Pereira","year":"2015","unstructured":"Pereira JA, Rosado E, Bali M, Metens T, Chao SL. Pancreatic neuroendocrine tumors: correlation between histogram analysis of apparent diffusion coefficient maps and tumor grade. Abdom Imaging. 2015;40(8):3122\u20138.","journal-title":"Abdom Imaging"},{"key":"2697_CR214","doi-asserted-by":"crossref","unstructured":"Bevilacqua A, Calabro D, Malavasi S, Ricci C, Casadei R, Campana D et al. A [68Ga]Ga-DOTANOC PET\/CT Radiomic Model for Non-Invasive Prediction of Tumour Grade in Pancreatic Neuroendocrine Tumours. Diagnostics (Basel). 2021;11(5) :870.","DOI":"10.3390\/diagnostics11050870"},{"issue":"10","key":"2697_CR215","doi-asserted-by":"publisher","first-page":"1034","DOI":"10.1097\/MNM.0000000000001231","volume":"41","author":"H Onner","year":"2020","unstructured":"Onner H, Abdulrezzak U, Tutus A. Could the skewness and kurtosis texture parameters of lesions obtained from pretreatment Ga-68 DOTA-TATE PET\/CT images predict receptor radionuclide therapy response in patients with gastroenteropancreatic neuroendocrine tumors? Nucl Med Commun. 2020;41(10):1034\u20139.","journal-title":"Nucl Med Commun"},{"issue":"3","key":"2697_CR216","doi-asserted-by":"publisher","first-page":"582","DOI":"10.1007\/s11307-018-1252-5","volume":"21","author":"RA Werner","year":"2019","unstructured":"Werner RA, Ilhan H, Lehner S, Papp L, Zsoter N, Schatka I, et al. Pre-therapy Somatostatin Receptor-Based Heterogeneity Predicts Overall Survival in Pancreatic Neuroendocrine Tumor Patients Undergoing Peptide Receptor Radionuclide Therapy. Mol Imaging Biol. 2019;21(3):582\u201390.","journal-title":"Mol Imaging Biol"},{"issue":"9","key":"2697_CR217","doi-asserted-by":"publisher","first-page":"896","DOI":"10.1097\/MNM.0000000000001236","volume":"41","author":"P Mapelli","year":"2020","unstructured":"Mapelli P, Partelli S, Salgarello M, Doraku J, Pasetto S, Rancoita PMV, et al. Dual tracer 68Ga-DOTATOC and 18F-FDG PET\/computed tomography radiomics in pancreatic neuroendocrine neoplasms: an endearing tool for preoperative risk assessment. Nucl Med Commun. 2020;41(9):896\u2013905.","journal-title":"Nucl Med Commun"},{"key":"2697_CR218","doi-asserted-by":"publisher","first-page":"108812","DOI":"10.1016\/j.ejrad.2020.108812","volume":"124","author":"I Martini","year":"2020","unstructured":"Martini I, Polici M, Zerunian M, Panzuto F, Rinzivillo M, Landolfi F, et al. CT texture analysis of liver metastases in PNETs versus NPNETs: Correlation with histopathological findings. Eur J Radiol. 2020;124:108812.","journal-title":"Eur J Radiol"},{"issue":"10","key":"2697_CR219","doi-asserted-by":"publisher","first-page":"833","DOI":"10.21037\/atm-21-25","volume":"9","author":"C Song","year":"2021","unstructured":"Song C, Wang M, Luo Y, Chen J, Peng Z, Wang Y, et al. Predicting the recurrence risk of pancreatic neuroendocrine neoplasms after radical resection using deep learning radiomics with preoperative computed tomography images. Ann Transl Med. 2021;9(10):833.","journal-title":"Ann Transl Med"},{"issue":"5","key":"2697_CR220","doi-asserted-by":"publisher","first-page":"753","DOI":"10.1016\/j.pan.2024.05.524","volume":"24","author":"B Ahn","year":"2024","unstructured":"Ahn B, Park HJ, Kim HJ, Hong SM. Radiologic tumor border can further stratify prognosis in patients with pancreatic neuroendocrine tumor. Pancreatology. 2024;24(5):753\u201363.","journal-title":"Pancreatology"},{"key":"2697_CR221","doi-asserted-by":"publisher","first-page":"65","DOI":"10.1016\/j.semcancer.2026.01.002","volume":"119","author":"M McKenzie","year":"2026","unstructured":"McKenzie M, Irac SE, Chen Z, Moradi A, Jenner A, Nguyen Q, et al. Integrative spatial omics and artificial intelligence: transforming cancer research with omics data and AI. Semin Cancer Biol. 2026;119:65\u201382.","journal-title":"Semin Cancer Biol"},{"issue":"1","key":"2697_CR222","doi-asserted-by":"publisher","first-page":"129","DOI":"10.1186\/s12943-024-02040-9","volume":"23","author":"Y Jin","year":"2024","unstructured":"Jin Y, Zuo Y, Li G, Liu W, Pan Y, Fan T, et al. Advances in spatial transcriptomics and its applications in cancer research. Mol Cancer. 2024;23(1):129.","journal-title":"Mol Cancer"},{"issue":"3","key":"2697_CR223","doi-asserted-by":"publisher","first-page":"659","DOI":"10.1002\/1878-0261.13727","volume":"19","author":"H Niedra","year":"2025","unstructured":"Niedra H, Peculis R, Saksis R, Mandrika I, Vilisova S, Nazarovs J, et al. Tumor and alpha-SMA-expressing stromal cells in pancreatic neuroendocrine tumors have a distinct RNA profile depending on tumor grade. Mol Oncol. 2025;19(3):659\u201381.","journal-title":"Mol Oncol"},{"issue":"1","key":"2697_CR224","doi-asserted-by":"publisher","first-page":"24","DOI":"10.1016\/j.ccell.2025.12.009","volume":"44","author":"Y Liu","year":"2026","unstructured":"Liu Y, Dai Y, Wang L. Spatial omics at the forefront: emerging technologies, analytical innovations, and clinical applications. Cancer Cell. 2026;44(1):24\u201349.","journal-title":"Cancer Cell"},{"issue":"9","key":"2697_CR225","first-page":"225","volume":"16","author":"JH Park","year":"2023","unstructured":"Park JH, Shin SJ, Jeon N, Lim BJ. Clinicopathologic characteristics of neuroendocrine tumors with assessment by digital image analysis for Ki-67 index with a focus on the gastroenteropancreatic tract: a single-center study. Int J Clin Exp Pathol. 2023;16(9):225\u201334.","journal-title":"Int J Clin Exp Pathol"},{"key":"2697_CR226","doi-asserted-by":"publisher","first-page":"593211","DOI":"10.3389\/fonc.2020.593211","volume":"10","author":"S Klimov","year":"2020","unstructured":"Klimov S, Xue Y, Gertych A, Graham RP, Jiang Y, Bhattarai S, et al. Predicting Metastasis Risk in Pancreatic Neuroendocrine Tumors Using Deep Learning Image Analysis. Front Oncol. 2020;10:593211.","journal-title":"Front Oncol"}],"container-title":["Molecular Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12943-026-02697-4","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12943-026-02697-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12943-026-02697-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,31]],"date-time":"2026-07-31T01:23:14Z","timestamp":1785460994000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1186\/s12943-026-02697-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5,29]]},"references-count":226,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["2697"],"URL":"https:\/\/doi.org\/10.1186\/s12943-026-02697-4","relation":{},"ISSN":["1476-4598"],"issn-type":[{"value":"1476-4598","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,5,29]]},"assertion":[{"value":"5 February 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 May 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"29 May 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Not applicable (review of the literature).","order":1,"name":"Ethics","label":"Ethics approval and consent to participate","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable (review of the literature).","order":2,"name":"Ethics","label":"Consent for publication","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"All the authors have no competing interest that can influence the results and\/or discussion reported in this paper. Regarding competing interest outside this study, the full disclosure is as follows: Aldo Scarpa reports honoraria from Incyte, MSD, and Medica (consulting and speaker bureau) and Claudio Luchini reports honoraria from Astellas (consulting and advisory board), and from Bayer, MSD, Gilead sciences, and Medica s.r.l. (consulting and speaker bureau). The other authors have no competing interest to declare.","order":3,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Declarations"}}],"article-number":"186"}}